PH12014502166B1 - Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases - Google Patents

Info

Publication number

PH12014502166B1

PH12014502166B1 PH12014502166A PH12014502166A PH12014502166B1 PH 12014502166 B1 PH12014502166 B1 PH 12014502166B1 PH 12014502166 A PH12014502166 A PH 12014502166A PH 12014502166 A PH12014502166 A PH 12014502166A PH 12014502166 B1 PH12014502166 B1 PH 12014502166B1

Authority

PH

Philippines

Prior art keywords

substituted

unsubstituted

triazolo

pyridin

methyl

Prior art date

2012-03-30

Links

• Espacenet
• Global Dossier
• Discuss

• -1 3,5-disubstituted-3h-imidazo[4,5-b]pyridine Chemical class 0.000 title claims description 142
• 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 title abstract description 3
• 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 title abstract 2
• 150000001875 compounds Chemical class 0.000 claims abstract description 365
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 96
• 201000010099 disease Diseases 0.000 claims abstract description 66
• 238000011282 treatment Methods 0.000 claims abstract description 54
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 41
• 208000035475 disorder Diseases 0.000 claims abstract description 30
• 206010028980 Neoplasm Diseases 0.000 claims description 98
• 125000000217 alkyl group Chemical group 0.000 claims description 79
• 239000000203 mixture Substances 0.000 claims description 61
• 210000004027 cell Anatomy 0.000 claims description 56
• 229910052739 hydrogen Inorganic materials 0.000 claims description 56
• 239000001257 hydrogen Substances 0.000 claims description 53
• 201000011510 cancer Diseases 0.000 claims description 51
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 48
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 47
• KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 45
• 229910052736 halogen Inorganic materials 0.000 claims description 45
• 150000002367 halogens Chemical class 0.000 claims description 44
• 108091000080 Phosphotransferase Proteins 0.000 claims description 43
• 102000020233 phosphotransferase Human genes 0.000 claims description 43
• 239000003112 inhibitor Substances 0.000 claims description 42
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 38
• 150000002431 hydrogen Chemical class 0.000 claims description 38
• 239000003814 drug Substances 0.000 claims description 35
• 150000003839 salts Chemical class 0.000 claims description 34
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
• 230000002401 inhibitory effect Effects 0.000 claims description 30
• 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims description 29
• 229910052757 nitrogen Inorganic materials 0.000 claims description 29
• 125000000304 alkynyl group Chemical group 0.000 claims description 27
• 125000003342 alkenyl group Chemical group 0.000 claims description 24
• 125000000392 cycloalkenyl group Chemical group 0.000 claims description 23
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 22
• 201000009030 Carcinoma Diseases 0.000 claims description 20
• 125000004429 atom Chemical group 0.000 claims description 20
• 125000003118 aryl group Chemical group 0.000 claims description 19
• 229910052799 carbon Inorganic materials 0.000 claims description 19
• 125000001072 heteroaryl group Chemical group 0.000 claims description 19
• 125000005842 heteroatom Chemical group 0.000 claims description 18
• 201000001441 melanoma Diseases 0.000 claims description 18
• 125000001424 substituent group Chemical group 0.000 claims description 18
• 206010025323 Lymphomas Diseases 0.000 claims description 17
• 125000003545 alkoxy group Chemical group 0.000 claims description 17
• 125000004432 carbon atom Chemical group C* 0.000 claims description 17
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
• 239000002246 antineoplastic agent Substances 0.000 claims description 15
• 229910052760 oxygen Inorganic materials 0.000 claims description 15
• 229920006395 saturated elastomer Polymers 0.000 claims description 15
• 206010041823 squamous cell carcinoma Diseases 0.000 claims description 15
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
• 125000000623 heterocyclic group Chemical group 0.000 claims description 13
• 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 13
• 229940124597 therapeutic agent Drugs 0.000 claims description 13
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
• 150000001204 N-oxides Chemical class 0.000 claims description 11
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 11
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
• 239000011734 sodium Substances 0.000 claims description 11
• 229910052717 sulfur Inorganic materials 0.000 claims description 11
• 206010003571 Astrocytoma Diseases 0.000 claims description 10
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 10
• 208000007766 Kaposi sarcoma Diseases 0.000 claims description 10
• 206010027476 Metastases Diseases 0.000 claims description 10
• 206010039491 Sarcoma Diseases 0.000 claims description 10
• 230000008901 benefit Effects 0.000 claims description 10
• 125000004122 cyclic group Chemical group 0.000 claims description 10
• 125000001153 fluoro group Chemical group F* 0.000 claims description 10
• 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 10
• 208000032839 leukemia Diseases 0.000 claims description 10
• 230000002062 proliferating effect Effects 0.000 claims description 10
• 208000011580 syndromic disease Diseases 0.000 claims description 10
• 210000001685 thyroid gland Anatomy 0.000 claims description 10
• 201000008808 Fibrosarcoma Diseases 0.000 claims description 9
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 9
• 230000001154 acute effect Effects 0.000 claims description 9
• 150000001408 amides Chemical class 0.000 claims description 9
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
• 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 9
• 208000017169 kidney disease Diseases 0.000 claims description 9
• 230000009401 metastasis Effects 0.000 claims description 9
• 229910052708 sodium Inorganic materials 0.000 claims description 9
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 8
• 206010061218 Inflammation Diseases 0.000 claims description 8
• 230000004054 inflammatory process Effects 0.000 claims description 8
• 210000004185 liver Anatomy 0.000 claims description 8
• 210000001428 peripheral nervous system Anatomy 0.000 claims description 8
• 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 8
• 206010018338 Glioma Diseases 0.000 claims description 7
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 7
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 7
• 125000002619 bicyclic group Chemical group 0.000 claims description 7
• 230000005764 inhibitory process Effects 0.000 claims description 7
• 210000003734 kidney Anatomy 0.000 claims description 7
• 208000019423 liver disease Diseases 0.000 claims description 7
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 7
• 230000019491 signal transduction Effects 0.000 claims description 7
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 6
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 6
• 208000032612 Glial tumor Diseases 0.000 claims description 6
• 208000017604 Hodgkin disease Diseases 0.000 claims description 6
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 6
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
• SNIABFMMCKVXSY-UHFFFAOYSA-N benzoylazanium;chloride Chemical compound Cl.NC(=O)C1=CC=CC=C1 SNIABFMMCKVXSY-UHFFFAOYSA-N 0.000 claims description 6
• 229910052731 fluorine Inorganic materials 0.000 claims description 6
• 201000005787 hematologic cancer Diseases 0.000 claims description 6
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 6
• 208000007538 neurilemmoma Diseases 0.000 claims description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
• 206010009944 Colon cancer Diseases 0.000 claims description 5
• 208000018142 Leiomyosarcoma Diseases 0.000 claims description 5
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 5
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
• 201000010208 Seminoma Diseases 0.000 claims description 5
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
• 206010041067 Small cell lung cancer Diseases 0.000 claims description 5
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
• 201000010881 cervical cancer Diseases 0.000 claims description 5
• 206010017758 gastric cancer Diseases 0.000 claims description 5
• 208000005017 glioblastoma Diseases 0.000 claims description 5
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
• 210000000987 immune system Anatomy 0.000 claims description 5
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
• 201000008968 osteosarcoma Diseases 0.000 claims description 5
• 208000000587 small cell lung carcinoma Diseases 0.000 claims description 5
• 201000011549 stomach cancer Diseases 0.000 claims description 5
• 230000004614 tumor growth Effects 0.000 claims description 5
• 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
• 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 4
• 206010027406 Mesothelioma Diseases 0.000 claims description 4
• 206010033128 Ovarian cancer Diseases 0.000 claims description 4
• 206010060862 Prostate cancer Diseases 0.000 claims description 4
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
• 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 4
• 208000008383 Wilms tumor Diseases 0.000 claims description 4
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 4
• 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 239000000945 filler Substances 0.000 claims description 4
• 230000003325 follicular Effects 0.000 claims description 4
• 206010039667 schwannoma Diseases 0.000 claims description 4
• 201000000849 skin cancer Diseases 0.000 claims description 4
• 150000003431 steroids Chemical class 0.000 claims description 4
• 206010042863 synovial sarcoma Diseases 0.000 claims description 4
• 201000002510 thyroid cancer Diseases 0.000 claims description 4
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims description 3
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
• 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
• 206010029260 Neuroblastoma Diseases 0.000 claims description 3
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
• 239000000739 antihistaminic agent Substances 0.000 claims description 3
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
• 201000004101 esophageal cancer Diseases 0.000 claims description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Substances OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 3
• 201000010175 gallbladder cancer Diseases 0.000 claims description 3
• 239000003018 immunosuppressive agent Substances 0.000 claims description 3
• 229940125721 immunosuppressive agent Drugs 0.000 claims description 3
• 208000003747 lymphoid leukemia Diseases 0.000 claims description 3
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
• 208000025113 myeloid leukemia Diseases 0.000 claims description 3
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 3
• 229940127084 other anti-cancer agent Drugs 0.000 claims description 3
• 201000002528 pancreatic cancer Diseases 0.000 claims description 3
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
• 239000000843 powder Substances 0.000 claims description 3
• 208000001608 teratocarcinoma Diseases 0.000 claims description 3
• ACCHIFNLELBPIZ-UHFFFAOYSA-N 2,6-difluoro-n-(2-hydroxyethoxy)-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(F)C(C(=O)NOCCO)=C(F)C=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 ACCHIFNLELBPIZ-UHFFFAOYSA-N 0.000 claims description 2
• KUWOYAHXKPUNPD-UHFFFAOYSA-N 2-[[2-methyl-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]phenyl]methylamino]ethyl acetate Chemical compound C(C)(=O)OCCNCC1=C(C=C(C=C1)C1=CC=C2C(=N1)N(N=N2)CC=2C=C1C=CC=NC1=CC2)C KUWOYAHXKPUNPD-UHFFFAOYSA-N 0.000 claims description 2
• ZPZAHZIPKLJTKC-UHFFFAOYSA-N 2-chloro-n-(2-hydroxy-2-methylpropoxy)-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(Cl)C(C(=O)NOCC(C)(O)C)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 ZPZAHZIPKLJTKC-UHFFFAOYSA-N 0.000 claims description 2
• QFAMPEGUHUPIPJ-UHFFFAOYSA-N 2-fluoro-4-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]-n-(2-hydroxyethoxy)benzamide Chemical compound C1=C(F)C(C(=O)NOCCO)=CC=C1C1=CC=C(N=NN2CC=3C(=CC4=NC=CC=C4C=3)F)C2=N1 QFAMPEGUHUPIPJ-UHFFFAOYSA-N 0.000 claims description 2
• NHXSTXWKZVAVOQ-UHFFFAOYSA-N Ethyl furoate Chemical compound CCOC(=O)C1=CC=CO1 NHXSTXWKZVAVOQ-UHFFFAOYSA-N 0.000 claims description 2
• 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
• 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 2
• 239000004743 Polypropylene Substances 0.000 claims description 2
• 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
• 201000008275 breast carcinoma Diseases 0.000 claims description 2
• 230000003197 catalytic effect Effects 0.000 claims description 2
• 230000009033 hematopoietic malignancy Effects 0.000 claims description 2
• 201000005296 lung carcinoma Diseases 0.000 claims description 2
• NSGGWDOXBDJQPF-UHFFFAOYSA-N n-(2-hydroxyethoxy)-2-methyl-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide;hydrobromide Chemical compound Br.C1=C(C(=O)NOCCO)C(C)=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 NSGGWDOXBDJQPF-UHFFFAOYSA-N 0.000 claims description 2
• 229920001155 polypropylene Polymers 0.000 claims description 2
• 239000011148 porous material Substances 0.000 claims description 2
• QSVSMLSZVBDQPS-UHFFFAOYSA-M sodium [2-chloro-4-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]benzoyl]-(2-hydroxyethoxy)azanide Chemical compound [Na+].OCCO[N-]C(=O)c1ccc(cc1Cl)-c1ccc2nnn(Cc3cc4cccnc4cc3F)c2n1 QSVSMLSZVBDQPS-UHFFFAOYSA-M 0.000 claims description 2
• 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 2
• RFZIABSNVBPYLS-UHFFFAOYSA-N 2-chloro-n-(2-hydroxyethoxy)-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(Cl)C(C(=O)NOCCO)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 RFZIABSNVBPYLS-UHFFFAOYSA-N 0.000 claims 2
• PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims 2
• GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 2
• 230000000202 analgesic effect Effects 0.000 claims 2
• 230000001387 anti-histamine Effects 0.000 claims 2
• 239000011347 resin Substances 0.000 claims 2
• 229920005989 resin Polymers 0.000 claims 2
• 238000007789 sealing Methods 0.000 claims 2
• RMEXFPUISNCOIL-UHFFFAOYSA-N 2,6-difluoro-4-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]-n-(2-hydroxyethoxy)benzamide Chemical compound C1=C(F)C(C(=O)NOCCO)=C(F)C=C1C1=CC=C(N=NN2CC=3C(=CC4=NC=CC=C4C=3)F)C2=N1 RMEXFPUISNCOIL-UHFFFAOYSA-N 0.000 claims 1
• KJKPUAGXGNQSAJ-UHFFFAOYSA-N 2,6-difluoro-n-(2-hydroxyethoxy)-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide;hydrochloride Chemical compound Cl.C1=C(F)C(C(=O)NOCCO)=C(F)C=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 KJKPUAGXGNQSAJ-UHFFFAOYSA-N 0.000 claims 1
• AMBIECVRXDPEAT-UHFFFAOYSA-N 2,6-difluoro-n-(2-hydroxyethoxy)-4-[3-[(2-methylquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=CC2=NC(C)=CC=C2C=C1CN(C1=N2)N=NC1=CC=C2C1=CC(F)=C(C(=O)NOCCO)C(F)=C1 AMBIECVRXDPEAT-UHFFFAOYSA-N 0.000 claims 1
• KMWCXEIKLSQZBU-UHFFFAOYSA-N 2-[[2-chloro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]phenyl]methylamino]ethyl 2,2-dimethylpropanoate Chemical compound C(C(C)(C)C)(=O)OCCNCC1=C(C=C(C=C1)C1=CC=C2C(=N1)N(N=N2)CC=2C=C1C=CC=NC1=CC2)Cl KMWCXEIKLSQZBU-UHFFFAOYSA-N 0.000 claims 1
• WBTUENDNCNRKNS-UHFFFAOYSA-N 2-[[2-chloro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]phenyl]methylamino]ethyl 2-benzamidoacetate Chemical compound C(C1=CC=CC=C1)(=O)NCC(=O)OCCNCC1=C(C=C(C=C1)C1=CC=C2C(=N1)N(N=N2)CC=2C=C1C=CC=NC1=CC2)Cl WBTUENDNCNRKNS-UHFFFAOYSA-N 0.000 claims 1
• QTNCJSJEVJJOPS-UHFFFAOYSA-N 2-[[2-chloro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]phenyl]methylamino]ethyl 2-methylpropanoate Chemical compound C(C(C)C)(=O)OCCNCC1=C(C=C(C=C1)C1=CC=C2C(=N1)N(N=N2)CC=2C=C1C=CC=NC1=CC2)Cl QTNCJSJEVJJOPS-UHFFFAOYSA-N 0.000 claims 1
• JEJZZDLDMKTUNX-UHFFFAOYSA-N 2-[[2-methyl-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]phenyl]methylamino]ethyl 2,2-dimethylpropanoate Chemical compound C(C(C)(C)C)(=O)OCCNCC1=C(C=C(C=C1)C1=CC=C2C(=N1)N(N=N2)CC=2C=C1C=CC=NC1=CC2)C JEJZZDLDMKTUNX-UHFFFAOYSA-N 0.000 claims 1
• JDSXBEKOKRUWGK-UHFFFAOYSA-N 2-[[2-methyl-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]phenyl]methylamino]ethyl 2-methylpropanoate Chemical compound C(C(C)C)(=O)OCCNCC1=C(C=C(C=C1)C1=CC=C2C(=N1)N(N=N2)CC=2C=C1C=CC=NC1=CC2)C JDSXBEKOKRUWGK-UHFFFAOYSA-N 0.000 claims 1
• AXXPOAAWKUOFKS-UHFFFAOYSA-N 2-[[2-methyl-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]phenyl]methylamino]ethyl benzoate Chemical compound C(C1=CC=CC=C1)(=O)OCCNCC1=C(C=C(C=C1)C1=CC=C2C(=N1)N(N=N2)CC=2C=C1C=CC=NC1=CC2)C AXXPOAAWKUOFKS-UHFFFAOYSA-N 0.000 claims 1
• JUNRYTMMLZWYSB-UHFFFAOYSA-N 2-chloro-4-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]-n-(2-hydroxyethoxy)benzamide;hydrochloride Chemical compound Cl.C1=C(Cl)C(C(=O)NOCCO)=CC=C1C1=CC=C(N=NN2CC=3C(=CC4=NC=CC=C4C=3)F)C2=N1 JUNRYTMMLZWYSB-UHFFFAOYSA-N 0.000 claims 1
• HQGFFWGLPKXKFX-UHFFFAOYSA-N 2-chloro-n-(1-hydroxy-2-methylpropan-2-yl)oxy-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(Cl)C(C(=O)NOC(C)(CO)C)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 HQGFFWGLPKXKFX-UHFFFAOYSA-N 0.000 claims 1
• AANWETBHUPWKPH-UHFFFAOYSA-N 2-chloro-n-(2-hydroxyethoxy)-4-[3-[(2-methylquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=CC2=NC(C)=CC=C2C=C1CN(C1=N2)N=NC1=CC=C2C1=CC=C(C(=O)NOCCO)C(Cl)=C1 AANWETBHUPWKPH-UHFFFAOYSA-N 0.000 claims 1
• XHQRFUBZEUFYTD-UHFFFAOYSA-N 2-chloro-n-(2-hydroxypropoxy)-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(Cl)C(C(=O)NOCC(O)C)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 XHQRFUBZEUFYTD-UHFFFAOYSA-N 0.000 claims 1
• XHQRFUBZEUFYTD-OAHLLOKOSA-N 2-chloro-n-[(2r)-2-hydroxypropoxy]-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(Cl)C(C(=O)NOC[C@H](O)C)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 XHQRFUBZEUFYTD-OAHLLOKOSA-N 0.000 claims 1
• XHQRFUBZEUFYTD-HNNXBMFYSA-N 2-chloro-n-[(2s)-2-hydroxypropoxy]-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(Cl)C(C(=O)NOC[C@@H](O)C)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 XHQRFUBZEUFYTD-HNNXBMFYSA-N 0.000 claims 1
• ALANNWOFXZKJHF-UHFFFAOYSA-N 4-[3-(1,3-benzothiazol-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]-2,6-difluoro-n-(2-hydroxyethoxy)benzamide Chemical compound C1=C(F)C(C(=O)NOCCO)=C(F)C=C1C1=CC=C(N=NN2CC=3C=C4SC=NC4=CC=3)C2=N1 ALANNWOFXZKJHF-UHFFFAOYSA-N 0.000 claims 1
• VHFPHHMYYPAYTL-UHFFFAOYSA-N 4-[3-(1,3-benzothiazol-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]-2-chloro-n-(2-hydroxyethoxy)benzamide Chemical compound C1=C(Cl)C(C(=O)NOCCO)=CC=C1C1=CC=C(N=NN2CC=3C=C4SC=NC4=CC=3)C2=N1 VHFPHHMYYPAYTL-UHFFFAOYSA-N 0.000 claims 1
• PGKXMDINDCXFBR-UHFFFAOYSA-N 4-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]-n-(2-hydroxyethoxy)-2-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(C(=O)NOCCO)=CC=C1C1=CC=C(N=NN2CC=3C(=CC4=NC=CC=C4C=3)F)C2=N1 PGKXMDINDCXFBR-UHFFFAOYSA-N 0.000 claims 1
• ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims 1
• 229910000013 Ammonium bicarbonate Inorganic materials 0.000 claims 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
• 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 claims 1
• 239000004677 Nylon Substances 0.000 claims 1
• 241001499733 Plantago asiatica Species 0.000 claims 1
• 235000003421 Plantago ovata Nutrition 0.000 claims 1
• 239000009223 Psyllium Substances 0.000 claims 1
• 239000004115 Sodium Silicate Substances 0.000 claims 1
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
• 206010042971 T-cell lymphoma Diseases 0.000 claims 1
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
• 241000607479 Yersinia pestis Species 0.000 claims 1
• 235000012538 ammonium bicarbonate Nutrition 0.000 claims 1
• 239000001099 ammonium carbonate Substances 0.000 claims 1
• 239000000440 bentonite Substances 0.000 claims 1
• 229910000278 bentonite Inorganic materials 0.000 claims 1
• SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims 1
• QDKFWHFXUNNUGZ-UHFFFAOYSA-N benzamide;hydron;bromide Chemical compound Br.NC(=O)C1=CC=CC=C1 QDKFWHFXUNNUGZ-UHFFFAOYSA-N 0.000 claims 1
• 229910021538 borax Inorganic materials 0.000 claims 1
• 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
• 230000007797 corrosion Effects 0.000 claims 1
• 238000005260 corrosion Methods 0.000 claims 1
• 229920001971 elastomer Polymers 0.000 claims 1
• ROBXZHNBBCHEIQ-UHFFFAOYSA-N ethyl 2-aminopropanoate Chemical compound CCOC(=O)C(C)N ROBXZHNBBCHEIQ-UHFFFAOYSA-N 0.000 claims 1
• 229910021485 fumed silica Inorganic materials 0.000 claims 1
• 239000010903 husk Substances 0.000 claims 1
• 229920001684 low density polyethylene Polymers 0.000 claims 1
• 239000004702 low-density polyethylene Substances 0.000 claims 1
• SPEHFEHTHJMPQA-UHFFFAOYSA-N n-(2-hydroxy-2-methylpropoxy)-2-methyl-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(C(=O)NOCC(C)(C)O)C(C)=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 SPEHFEHTHJMPQA-UHFFFAOYSA-N 0.000 claims 1
• PYGDMTGBUDHNTR-UHFFFAOYSA-N n-(2-hydroxyethoxy)-2-methyl-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(C(=O)NOCCO)C(C)=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 PYGDMTGBUDHNTR-UHFFFAOYSA-N 0.000 claims 1
• IZJMUKQLTCIHNP-UHFFFAOYSA-N n-(2-hydroxyethoxy)-2-methyl-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C1=C(C(=O)NOCCO)C(C)=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 IZJMUKQLTCIHNP-UHFFFAOYSA-N 0.000 claims 1
• FBPCXMKGZRFBTL-UHFFFAOYSA-N n-(2-hydroxyethoxy)-2-methyl-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide;hydrochloride Chemical compound Cl.C1=C(C(=O)NOCCO)C(C)=CC(C=2N=C3N(CC=4C=C5C=CC=NC5=CC=4)N=NC3=CC=2)=C1 FBPCXMKGZRFBTL-UHFFFAOYSA-N 0.000 claims 1
• YVRBWLQYYXUGNX-UHFFFAOYSA-N n-(2-hydroxyethoxy)-2-methyl-4-[3-[(1-oxidoquinolin-1-ium-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(C(=O)NOCCO)C(C)=CC(C=2N=C3N(CC=4C=C5C=CC=[N+]([O-])C5=CC=4)N=NC3=CC=2)=C1 YVRBWLQYYXUGNX-UHFFFAOYSA-N 0.000 claims 1
• 229920001778 nylon Polymers 0.000 claims 1
• 239000004033 plastic Substances 0.000 claims 1
• 229920003023 plastic Polymers 0.000 claims 1
• 229920000058 polyacrylate Polymers 0.000 claims 1
• 229940070687 psyllium Drugs 0.000 claims 1
• KSROGBCLOUKHHL-UHFFFAOYSA-M sodium [2,6-difluoro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzoyl]-(2-hydroxyethoxy)azanide Chemical compound [Na+].OCCO[N-]C(=O)c1c(F)cc(cc1F)-c1ccc2nnn(Cc3ccc4ncccc4c3)c2n1 KSROGBCLOUKHHL-UHFFFAOYSA-M 0.000 claims 1
• NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 claims 1
• 229910052911 sodium silicate Inorganic materials 0.000 claims 1
• 235000010339 sodium tetraborate Nutrition 0.000 claims 1
• 239000000375 suspending agent Substances 0.000 claims 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims 1
• BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims 1
• 239000000230 xanthan gum Substances 0.000 claims 1
• 229920001285 xanthan gum Polymers 0.000 claims 1
• 229940082509 xanthan gum Drugs 0.000 claims 1
• 235000010493 xanthan gum Nutrition 0.000 claims 1
• 238000000034 method Methods 0.000 abstract description 118
• 230000001404 mediated effect Effects 0.000 abstract description 7
• 230000002265 prevention Effects 0.000 abstract description 5
• 239000000543 intermediate Substances 0.000 description 102
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 96
• 239000007787 solid Substances 0.000 description 96
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 93
• 239000003795 chemical substances by application Substances 0.000 description 73
• 239000000243 solution Substances 0.000 description 61
• 230000000694 effects Effects 0.000 description 59
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 54
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 40
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 40
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 35
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 32
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 32
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
• 239000002585 base Substances 0.000 description 28
• 238000005160 1H NMR spectroscopy Methods 0.000 description 26
• 241000124008 Mammalia Species 0.000 description 25
• 102000001253 Protein Kinase Human genes 0.000 description 24
• 108060006633 protein kinase Proteins 0.000 description 24
• 150000002148 esters Chemical class 0.000 description 23
• 239000011541 reaction mixture Substances 0.000 description 23
• 102000005962 receptors Human genes 0.000 description 23
• 108020003175 receptors Proteins 0.000 description 23
• 208000009956 adenocarcinoma Diseases 0.000 description 22
• 210000001519 tissue Anatomy 0.000 description 22
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 21
• 239000003208 petroleum Substances 0.000 description 20
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 20
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 19
• 239000002253 acid Substances 0.000 description 19
• 108090000623 proteins and genes Proteins 0.000 description 19
• 210000000988 bone and bone Anatomy 0.000 description 18
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
• 230000000921 morphogenic effect Effects 0.000 description 17
• 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 16
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 16
• 229940079593 drug Drugs 0.000 description 16
• 235000011056 potassium acetate Nutrition 0.000 description 16
• 102000004169 proteins and genes Human genes 0.000 description 16
• 229910052938 sodium sulfate Inorganic materials 0.000 description 16
• 235000011152 sodium sulphate Nutrition 0.000 description 16
• 230000001225 therapeutic effect Effects 0.000 description 16
• 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 15
• 241001465754 Metazoa Species 0.000 description 15
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 15
• 230000012010 growth Effects 0.000 description 15
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
• 239000003054 catalyst Substances 0.000 description 14
• 210000000056 organ Anatomy 0.000 description 14
• 229940002612 prodrug Drugs 0.000 description 14
• 239000000651 prodrug Substances 0.000 description 14
• 235000018102 proteins Nutrition 0.000 description 14
• CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 14
• LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 14
• 102000004190 Enzymes Human genes 0.000 description 12
• 108090000790 Enzymes Proteins 0.000 description 12
• 201000004681 Psoriasis Diseases 0.000 description 12
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
• 229940088598 enzyme Drugs 0.000 description 12
• 230000005855 radiation Effects 0.000 description 12
• 238000003419 tautomerization reaction Methods 0.000 description 12
• 229910052723 transition metal Inorganic materials 0.000 description 12
• 150000003624 transition metals Chemical class 0.000 description 12
• 201000001320 Atherosclerosis Diseases 0.000 description 11
• 102000004127 Cytokines Human genes 0.000 description 11
• 108090000695 Cytokines Proteins 0.000 description 11
• 230000002159 abnormal effect Effects 0.000 description 11
• 238000006243 chemical reaction Methods 0.000 description 11
• 239000003102 growth factor Substances 0.000 description 11
• 229940043355 kinase inhibitor Drugs 0.000 description 11
• 206010025135 lupus erythematosus Diseases 0.000 description 11
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 11
• 150000003254 radicals Chemical class 0.000 description 11
• 238000001959 radiotherapy Methods 0.000 description 11
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 11
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 11
• 208000023275 Autoimmune disease Diseases 0.000 description 10
• 229940124639 Selective inhibitor Drugs 0.000 description 10
• 229910000027 potassium carbonate Inorganic materials 0.000 description 10
• 210000002307 prostate Anatomy 0.000 description 10
• 230000004083 survival effect Effects 0.000 description 10
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
• 239000002202 Polyethylene glycol Substances 0.000 description 9
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 9
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 9
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
• 206010003246 arthritis Diseases 0.000 description 9
• 210000000481 breast Anatomy 0.000 description 9
• 206010012601 diabetes mellitus Diseases 0.000 description 9
• 238000009472 formulation Methods 0.000 description 9
• 230000006870 function Effects 0.000 description 9
• 238000001727 in vivo Methods 0.000 description 9
• XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
• 210000004072 lung Anatomy 0.000 description 9
• 239000012044 organic layer Substances 0.000 description 9
• 229920001223 polyethylene glycol Polymers 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• 230000004044 response Effects 0.000 description 9
• 210000003491 skin Anatomy 0.000 description 9
• 210000003932 urinary bladder Anatomy 0.000 description 9
• TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 8
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 8
• 201000004624 Dermatitis Diseases 0.000 description 8
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 8
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 8
• 108700003853 RON Proteins 0.000 description 8
• 229910021626 Tin(II) chloride Inorganic materials 0.000 description 8
• 206010052779 Transplant rejections Diseases 0.000 description 8
• 229910021529 ammonia Inorganic materials 0.000 description 8
• 208000006673 asthma Diseases 0.000 description 8
• ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 8
• 239000000969 carrier Substances 0.000 description 8
• 239000012043 crude product Substances 0.000 description 8
• 229940127089 cytotoxic agent Drugs 0.000 description 8
• 125000000219 ethylidene group Chemical group [H]C(=[*])C([H])([H])[H] 0.000 description 8
• 230000014509 gene expression Effects 0.000 description 8
• 230000002757 inflammatory effect Effects 0.000 description 8
• 230000035772 mutation Effects 0.000 description 8
• 229920000642 polymer Polymers 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 125000006239 protecting group Chemical group 0.000 description 8
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
• 229910000029 sodium carbonate Inorganic materials 0.000 description 8
• 239000002904 solvent Substances 0.000 description 8
• 239000001119 stannous chloride Substances 0.000 description 8
• 235000011150 stannous chloride Nutrition 0.000 description 8
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 7
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 7
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
• 239000003146 anticoagulant agent Substances 0.000 description 7
• 208000010668 atopic eczema Diseases 0.000 description 7
• 210000004556 brain Anatomy 0.000 description 7
• 239000012267 brine Substances 0.000 description 7
• 150000001721 carbon Chemical group 0.000 description 7
• 230000001684 chronic effect Effects 0.000 description 7
• 238000004440 column chromatography Methods 0.000 description 7
• 230000002496 gastric effect Effects 0.000 description 7
• 230000011664 signaling Effects 0.000 description 7
• 235000010288 sodium nitrite Nutrition 0.000 description 7
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 239000001117 sulphuric acid Substances 0.000 description 7
• 235000011149 sulphuric acid Nutrition 0.000 description 7
• 208000024891 symptom Diseases 0.000 description 7
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
• 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
• 102000001301 EGF receptor Human genes 0.000 description 6
• 108060006698 EGF receptor Proteins 0.000 description 6
• 208000004403 Prostatic Hyperplasia Diseases 0.000 description 6
• 229960001138 acetylsalicylic acid Drugs 0.000 description 6
• 239000004480 active ingredient Substances 0.000 description 6
• 208000026935 allergic disease Diseases 0.000 description 6
• 239000005557 antagonist Substances 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 230000010261 cell growth Effects 0.000 description 6
• 230000004663 cell proliferation Effects 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 230000028709 inflammatory response Effects 0.000 description 6
• 208000014674 injury Diseases 0.000 description 6
• 210000000265 leukocyte Anatomy 0.000 description 6
• 230000000670 limiting effect Effects 0.000 description 6
• 239000001301 oxygen Substances 0.000 description 6
• 230000037361 pathway Effects 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 230000009467 reduction Effects 0.000 description 6
• 238000006722 reduction reaction Methods 0.000 description 6
• 230000002829 reductive effect Effects 0.000 description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 description 6
• 150000003384 small molecules Chemical class 0.000 description 6
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
• 235000017557 sodium bicarbonate Nutrition 0.000 description 6
• 208000030507 AIDS Diseases 0.000 description 5
• 239000005711 Benzoic acid Substances 0.000 description 5
• BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
• 206010018364 Glomerulonephritis Diseases 0.000 description 5
• 206010020751 Hypersensitivity Diseases 0.000 description 5
• 239000005411 L01XE02 - Gefitinib Substances 0.000 description 5
• 208000002193 Pain Diseases 0.000 description 5
• 206010035664 Pneumonia Diseases 0.000 description 5
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 5
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 5
• 206010039710 Scleroderma Diseases 0.000 description 5
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 229940024606 amino acid Drugs 0.000 description 5
• 235000001014 amino acid Nutrition 0.000 description 5
• 150000001413 amino acids Chemical class 0.000 description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
• 230000001363 autoimmune Effects 0.000 description 5
• 235000010233 benzoic acid Nutrition 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 210000001185 bone marrow Anatomy 0.000 description 5
• 210000001072 colon Anatomy 0.000 description 5
• 238000002648 combination therapy Methods 0.000 description 5
• 230000006378 damage Effects 0.000 description 5
• 239000003085 diluting agent Substances 0.000 description 5
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 208000027866 inflammatory disease Diseases 0.000 description 5
• 238000002347 injection Methods 0.000 description 5
• 239000007924 injection Substances 0.000 description 5
• 208000020816 lung neoplasm Diseases 0.000 description 5
• 229960000485 methotrexate Drugs 0.000 description 5
• 230000002611 ovarian Effects 0.000 description 5
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
• 208000037803 restenosis Diseases 0.000 description 5
• 238000012552 review Methods 0.000 description 5
• 210000000130 stem cell Anatomy 0.000 description 5
• 210000002784 stomach Anatomy 0.000 description 5
• PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Natural products C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 5
• 230000001131 transforming effect Effects 0.000 description 5
• 238000002054 transplantation Methods 0.000 description 5
• 230000005747 tumor angiogenesis Effects 0.000 description 5
• 230000003612 virological effect Effects 0.000 description 5
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 4
• 208000032467 Aplastic anaemia Diseases 0.000 description 4
• 208000024172 Cardiovascular disease Diseases 0.000 description 4
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 4
• 241000701806 Human papillomavirus Species 0.000 description 4
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
• 208000034578 Multiple myelomas Diseases 0.000 description 4
• 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 4
• 229930012538 Paclitaxel Natural products 0.000 description 4
• 206010033645 Pancreatitis Diseases 0.000 description 4
• XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
• 208000009527 Refractory anemia Diseases 0.000 description 4
• 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 description 4
• 201000000582 Retinoblastoma Diseases 0.000 description 4
• 206010040047 Sepsis Diseases 0.000 description 4
• 206010040070 Septic Shock Diseases 0.000 description 4
• 208000006011 Stroke Diseases 0.000 description 4
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
• 206010047115 Vasculitis Diseases 0.000 description 4
• 230000009471 action Effects 0.000 description 4
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 4
• 230000033115 angiogenesis Effects 0.000 description 4
• 239000004037 angiogenesis inhibitor Substances 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 230000001028 anti-proliverative effect Effects 0.000 description 4
• 230000037396 body weight Effects 0.000 description 4
• 239000011575 calcium Substances 0.000 description 4
• 208000002458 carcinoid tumor Diseases 0.000 description 4
• 238000012512 characterization method Methods 0.000 description 4
• 230000008878 coupling Effects 0.000 description 4
• 238000010168 coupling process Methods 0.000 description 4
• 238000005859 coupling reaction Methods 0.000 description 4
• 230000001419 dependent effect Effects 0.000 description 4
• 238000010511 deprotection reaction Methods 0.000 description 4
• 230000002526 effect on cardiovascular system Effects 0.000 description 4
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
• WDAXFOBOLVPGLV-UHFFFAOYSA-N ethyl isobutyrate Chemical compound CCOC(=O)C(C)C WDAXFOBOLVPGLV-UHFFFAOYSA-N 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• 208000024908 graft versus host disease Diseases 0.000 description 4
• 125000005843 halogen group Chemical group 0.000 description 4
• 210000003128 head Anatomy 0.000 description 4
• 229940088597 hormone Drugs 0.000 description 4
• 239000005556 hormone Substances 0.000 description 4
• 230000003463 hyperproliferative effect Effects 0.000 description 4
• 125000001841 imino group Chemical group [H]N=* 0.000 description 4
• 230000028993 immune response Effects 0.000 description 4
• 230000001965 increasing effect Effects 0.000 description 4
• 230000004968 inflammatory condition Effects 0.000 description 4
• 229910052742 iron Inorganic materials 0.000 description 4
• 201000005202 lung cancer Diseases 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• 229910052751 metal Inorganic materials 0.000 description 4
• 239000002184 metal Substances 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 210000000214 mouth Anatomy 0.000 description 4
• 201000006417 multiple sclerosis Diseases 0.000 description 4
• 208000010125 myocardial infarction Diseases 0.000 description 4
• 210000001672 ovary Anatomy 0.000 description 4
• 125000004043 oxo group Chemical group O=* 0.000 description 4
• 229960001592 paclitaxel Drugs 0.000 description 4
• 230000000144 pharmacologic effect Effects 0.000 description 4
• 230000026731 phosphorylation Effects 0.000 description 4
• 238000006366 phosphorylation reaction Methods 0.000 description 4
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
• 230000000069 prophylactic effect Effects 0.000 description 4
• 230000002285 radioactive effect Effects 0.000 description 4
• 230000000241 respiratory effect Effects 0.000 description 4
• 125000006413 ring segment Chemical group 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
• 238000002560 therapeutic procedure Methods 0.000 description 4
• 206010044412 transitional cell carcinoma Diseases 0.000 description 4
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
• 230000005740 tumor formation Effects 0.000 description 4
• 229940088594 vitamin Drugs 0.000 description 4
• 235000013343 vitamin Nutrition 0.000 description 4
• 239000011782 vitamin Substances 0.000 description 4
• 229930003231 vitamin Natural products 0.000 description 4
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
• NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 3
• DJOMWLVGTUQULT-UHFFFAOYSA-N (3-chloro-4-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=C(B(O)O)C=C1Cl DJOMWLVGTUQULT-UHFFFAOYSA-N 0.000 description 3
• GLBZSOQDAOLMGC-UHFFFAOYSA-N 1-(2-hydroxy-2-methylpropyl)-n-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=C(C)N(CC(C)(C)O)N1C1=CC=CC=C1 GLBZSOQDAOLMGC-UHFFFAOYSA-N 0.000 description 3
• ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 3
• 206010003210 Arteriosclerosis Diseases 0.000 description 3
• 206010004146 Basal cell carcinoma Diseases 0.000 description 3
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
• 102000014914 Carrier Proteins Human genes 0.000 description 3
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
• 208000015943 Coeliac disease Diseases 0.000 description 3
• 208000011231 Crohn disease Diseases 0.000 description 3
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 3
• 206010016654 Fibrosis Diseases 0.000 description 3
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
• 208000007465 Giant cell arteritis Diseases 0.000 description 3
• 208000009329 Graft vs Host Disease Diseases 0.000 description 3
• 102000009465 Growth Factor Receptors Human genes 0.000 description 3
• 108010009202 Growth Factor Receptors Proteins 0.000 description 3
• ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 3
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 3
• 208000005615 Interstitial Cystitis Diseases 0.000 description 3
• 239000002067 L01XE06 - Dasatinib Substances 0.000 description 3
• 201000009906 Meningitis Diseases 0.000 description 3
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 3
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
• 238000005481 NMR spectroscopy Methods 0.000 description 3
• 101150057903 NRARP gene Proteins 0.000 description 3
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 3
• IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 3
• 208000007452 Plasmacytoma Diseases 0.000 description 3
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
• 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
• NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
• 208000006265 Renal cell carcinoma Diseases 0.000 description 3
• 206010063837 Reperfusion injury Diseases 0.000 description 3
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
• 210000001744 T-lymphocyte Anatomy 0.000 description 3
• 201000005969 Uveal melanoma Diseases 0.000 description 3
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 208000027418 Wounds and injury Diseases 0.000 description 3
• 230000003213 activating effect Effects 0.000 description 3
• 239000013543 active substance Substances 0.000 description 3
• 229910052783 alkali metal Inorganic materials 0.000 description 3
• 229940100198 alkylating agent Drugs 0.000 description 3
• 239000002168 alkylating agent Substances 0.000 description 3
• 230000000172 allergic effect Effects 0.000 description 3
• 230000007815 allergy Effects 0.000 description 3
• 230000000735 allogeneic effect Effects 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 235000019270 ammonium chloride Nutrition 0.000 description 3
• 239000003098 androgen Substances 0.000 description 3
• 239000003242 anti bacterial agent Substances 0.000 description 3
• 239000000427 antigen Substances 0.000 description 3
• 102000036639 antigens Human genes 0.000 description 3
• 108091007433 antigens Proteins 0.000 description 3
• 208000011775 arteriosclerosis disease Diseases 0.000 description 3
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 3
• 108091008324 binding proteins Proteins 0.000 description 3
• IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 3
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 3
• 206010006451 bronchitis Diseases 0.000 description 3
• 150000001720 carbohydrates Chemical class 0.000 description 3
• 235000014633 carbohydrates Nutrition 0.000 description 3
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
• 230000004709 cell invasion Effects 0.000 description 3
• 230000012292 cell migration Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 210000003169 central nervous system Anatomy 0.000 description 3
• 210000003679 cervix uteri Anatomy 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 239000002254 cytotoxic agent Substances 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
• 230000009977 dual effect Effects 0.000 description 3
• 230000004761 fibrosis Effects 0.000 description 3
• 229960002949 fluorouracil Drugs 0.000 description 3
• 235000019253 formic acid Nutrition 0.000 description 3
• 125000000524 functional group Chemical group 0.000 description 3
• 229960002584 gefitinib Drugs 0.000 description 3
• 230000003394 haemopoietic effect Effects 0.000 description 3
• 238000010438 heat treatment Methods 0.000 description 3
• 201000011066 hemangioma Diseases 0.000 description 3
• 229940022353 herceptin Drugs 0.000 description 3
• 208000002557 hidradenitis Diseases 0.000 description 3
• 230000007062 hydrolysis Effects 0.000 description 3
• 238000006460 hydrolysis reaction Methods 0.000 description 3
• 239000005457 ice water Substances 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 210000004969 inflammatory cell Anatomy 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 3
• 230000001678 irradiating effect Effects 0.000 description 3
• 230000000302 ischemic effect Effects 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 239000007788 liquid Substances 0.000 description 3
• 206010027191 meningioma Diseases 0.000 description 3
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
• 229910001507 metal halide Inorganic materials 0.000 description 3
• 150000005309 metal halides Chemical class 0.000 description 3
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 3
• 206010028417 myasthenia gravis Diseases 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• 210000000440 neutrophil Anatomy 0.000 description 3
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
• 201000002575 ocular melanoma Diseases 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 210000000496 pancreas Anatomy 0.000 description 3
• 239000006187 pill Substances 0.000 description 3
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
• 229910052700 potassium Inorganic materials 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 230000002685 pulmonary effect Effects 0.000 description 3
• 208000005069 pulmonary fibrosis Diseases 0.000 description 3
• 239000000018 receptor agonist Substances 0.000 description 3
• 229940044601 receptor agonist Drugs 0.000 description 3
• 238000011160 research Methods 0.000 description 3
• 201000000306 sarcoidosis Diseases 0.000 description 3
• 208000017520 skin disease Diseases 0.000 description 3
• 230000003637 steroidlike Effects 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 230000008961 swelling Effects 0.000 description 3
• 238000003786 synthesis reaction Methods 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 239000003826 tablet Substances 0.000 description 3
• 206010043207 temporal arteritis Diseases 0.000 description 3
• 150000003573 thiols Chemical class 0.000 description 3
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 3
• 230000002537 thrombolytic effect Effects 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• DNIOTHIAVRFCFK-UHFFFAOYSA-N (2,3-difluoro-4-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=C(B(O)O)C(F)=C1F DNIOTHIAVRFCFK-UHFFFAOYSA-N 0.000 description 2
• ABYZSYDGJGVCHS-ZETCQYMHSA-N (2s)-2-acetamido-n-(4-nitrophenyl)propanamide Chemical compound CC(=O)N[C@@H](C)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 ABYZSYDGJGVCHS-ZETCQYMHSA-N 0.000 description 2
• YZYGXFXSMDUXJT-UHFFFAOYSA-N (3-fluoro-4-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=C(B(O)O)C=C1F YZYGXFXSMDUXJT-UHFFFAOYSA-N 0.000 description 2
• PQCXFUXRTRESBD-UHFFFAOYSA-N (4-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=C(B(O)O)C=C1 PQCXFUXRTRESBD-UHFFFAOYSA-N 0.000 description 2
• IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
• FCGXLCNBWYIEAA-UHFFFAOYSA-N 1,3-benzothiazol-6-ylmethanamine Chemical compound NCC1=CC=C2N=CSC2=C1 FCGXLCNBWYIEAA-UHFFFAOYSA-N 0.000 description 2
• SHCWQWRTKPNTEM-UHFFFAOYSA-N 2,6-dichloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1Cl SHCWQWRTKPNTEM-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• UKNQSSBKXRDURG-UHFFFAOYSA-N 2-chloro-4-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(Cl)C(C(=O)N)=CC=C1C1=CC=C(N=CN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 UKNQSSBKXRDURG-UHFFFAOYSA-N 0.000 description 2
• KTTFZHAEQJJTEJ-UHFFFAOYSA-N 2-chloro-n-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide Chemical compound C1=C(Cl)C(C(=O)NC)=CC=C1B1OC(C)(C)C(C)(C)O1 KTTFZHAEQJJTEJ-UHFFFAOYSA-N 0.000 description 2
• RGNLKYMDERTWSG-UHFFFAOYSA-N 2-methylquinoline-6-carbonitrile Chemical compound C1=C(C#N)C=CC2=NC(C)=CC=C21 RGNLKYMDERTWSG-UHFFFAOYSA-N 0.000 description 2
• FMOAWYNLJWFXOH-UHFFFAOYSA-N 2-methylquinoline-6-carboxamide Chemical compound C1=C(C(N)=O)C=CC2=NC(C)=CC=C21 FMOAWYNLJWFXOH-UHFFFAOYSA-N 0.000 description 2
• 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 2
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
• GWRSATNRNFYMDI-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound FC=1C=C(NC=2N=C3N(C4CCCC4)CC(F)(F)C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)NC1CCN(C)CC1 GWRSATNRNFYMDI-UHFFFAOYSA-N 0.000 description 2
• VYGSRKKGNFFTNB-UHFFFAOYSA-N 4-bromo-2,6-difluorobenzamide Chemical compound NC(=O)C1=C(F)C=C(Br)C=C1F VYGSRKKGNFFTNB-UHFFFAOYSA-N 0.000 description 2
• GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 description 2
• 125000005986 4-piperidonyl group Chemical group 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• JRWCBEOAFGHNNU-UHFFFAOYSA-N 6-[difluoro-[6-(1-methyl-4-pyrazolyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl]quinoline Chemical compound C1=NN(C)C=C1C1=NN2C(C(F)(F)C=3C=C4C=CC=NC4=CC=3)=NN=C2C=C1 JRWCBEOAFGHNNU-UHFFFAOYSA-N 0.000 description 2
• IFIKQQLFQMNCRN-UHFFFAOYSA-N 6-bromo-7-fluoroquinoline Chemical compound C1=CC=C2C=C(Br)C(F)=CC2=N1 IFIKQQLFQMNCRN-UHFFFAOYSA-N 0.000 description 2
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
• XUIRHRWOJCYEDJ-UHFFFAOYSA-N 7-fluoroquinoline Chemical compound C1=CC=NC2=CC(F)=CC=C21 XUIRHRWOJCYEDJ-UHFFFAOYSA-N 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• 208000026872 Addison Disease Diseases 0.000 description 2
• 206010001767 Alopecia universalis Diseases 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
• 206010002198 Anaphylactic reaction Diseases 0.000 description 2
• 201000003076 Angiosarcoma Diseases 0.000 description 2
• 108010058207 Anistreplase Proteins 0.000 description 2
• 241000272517 Anseriformes Species 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
• 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
• 208000023328 Basedow disease Diseases 0.000 description 2
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 2
• 206010005003 Bladder cancer Diseases 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
• 201000000274 Carcinosarcoma Diseases 0.000 description 2
• 206010007559 Cardiac failure congestive Diseases 0.000 description 2
• 229940123587 Cell cycle inhibitor Drugs 0.000 description 2
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
• 241000272194 Ciconiiformes Species 0.000 description 2
• 206010009900 Colitis ulcerative Diseases 0.000 description 2
• 201000003883 Cystic fibrosis Diseases 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• 230000004544 DNA amplification Effects 0.000 description 2
• 108010092160 Dactinomycin Proteins 0.000 description 2
• 206010012438 Dermatitis atopic Diseases 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 206010014561 Emphysema Diseases 0.000 description 2
• 201000009273 Endometriosis Diseases 0.000 description 2
• 206010014824 Endotoxic shock Diseases 0.000 description 2
• 208000004232 Enteritis Diseases 0.000 description 2
• 206010014967 Ependymoma Diseases 0.000 description 2
• 102000050554 Eph Family Receptors Human genes 0.000 description 2
• 108091008815 Eph receptors Proteins 0.000 description 2
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
• 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
• 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
• 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
• 102000003956 Fibroblast growth factor 8 Human genes 0.000 description 2
• 208000007882 Gastritis Diseases 0.000 description 2
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 2
• 206010018366 Glomerulonephritis acute Diseases 0.000 description 2
• 206010018367 Glomerulonephritis chronic Diseases 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• QMXOFBXZEKTJIK-UHFFFAOYSA-N Glycinol Natural products C1=C(O)C=C2OCC3(O)C4=CC=C(O)C=C4OC3C2=C1 QMXOFBXZEKTJIK-UHFFFAOYSA-N 0.000 description 2
• 208000024869 Goodpasture syndrome Diseases 0.000 description 2
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 2
• 108010069236 Goserelin Proteins 0.000 description 2
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
• 208000015023 Graves' disease Diseases 0.000 description 2
• 208000001258 Hemangiosarcoma Diseases 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 2
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
• 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 2
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
• 208000005726 Inflammatory Breast Neoplasms Diseases 0.000 description 2
• 206010021980 Inflammatory carcinoma of the breast Diseases 0.000 description 2
• 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
• 108010005716 Interferon beta-1a Proteins 0.000 description 2
• 102000015696 Interleukins Human genes 0.000 description 2
• 108010063738 Interleukins Proteins 0.000 description 2
• 206010061252 Intraocular melanoma Diseases 0.000 description 2
• 208000000209 Isaacs syndrome Diseases 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
• 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 description 2
• 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• 201000002481 Myositis Diseases 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Chemical class CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
• 206010072359 Neuromyotonia Diseases 0.000 description 2
• 201000010133 Oligodendroglioma Diseases 0.000 description 2
• 208000003435 Optic Neuritis Diseases 0.000 description 2
• 206010031096 Oropharyngeal cancer Diseases 0.000 description 2
• 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 2
• 208000010191 Osteitis Deformans Diseases 0.000 description 2
• 208000001132 Osteoporosis Diseases 0.000 description 2
• 108091008606 PDGF receptors Proteins 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 208000027868 Paget disease Diseases 0.000 description 2
• 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• 208000007641 Pinealoma Diseases 0.000 description 2
• 102000003666 Placenta Growth Factor Human genes 0.000 description 2
• 108010082093 Placenta Growth Factor Proteins 0.000 description 2
• 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 2
• 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 2
• 206010036030 Polyarthritis Diseases 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 2
• 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
• 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 101500026845 Rattus norvegicus C3-beta-c Proteins 0.000 description 2
• 208000015634 Rectal Neoplasms Diseases 0.000 description 2
• 208000033464 Reiter syndrome Diseases 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 241000725643 Respiratory syncytial virus Species 0.000 description 2
• 208000017442 Retinal disease Diseases 0.000 description 2
• 206010038923 Retinopathy Diseases 0.000 description 2
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
• 206010039085 Rhinitis allergic Diseases 0.000 description 2
• LYUTUSMIPZZPHN-UHFFFAOYSA-N S1C=NC2=C1C=C(C=C2)CNC(OC(C)(C)C)=O Chemical compound S1C=NC2=C1C=C(C=C2)CNC(OC(C)(C)C)=O LYUTUSMIPZZPHN-UHFFFAOYSA-N 0.000 description 2
• 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
• 241000710960 Sindbis virus Species 0.000 description 2
• 108010056088 Somatostatin Proteins 0.000 description 2
• 102000005157 Somatostatin Human genes 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
• 208000001106 Takayasu Arteritis Diseases 0.000 description 2
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
• 208000024313 Testicular Neoplasms Diseases 0.000 description 2
• 206010057644 Testis cancer Diseases 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 2
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
• 201000006704 Ulcerative Colitis Diseases 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
• 208000002495 Uterine Neoplasms Diseases 0.000 description 2
• 206010046851 Uveitis Diseases 0.000 description 2
• 108091008605 VEGF receptors Proteins 0.000 description 2
• 206010046914 Vaginal infection Diseases 0.000 description 2
• 201000008100 Vaginitis Diseases 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• 206010047642 Vitiligo Diseases 0.000 description 2
• 208000003728 Vulvodynia Diseases 0.000 description 2
• 206010069055 Vulvovaginal pain Diseases 0.000 description 2
• PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• 208000004064 acoustic neuroma Diseases 0.000 description 2
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
• 208000002517 adenoid cystic carcinoma Diseases 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 230000001780 adrenocortical effect Effects 0.000 description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 150000001299 aldehydes Chemical class 0.000 description 2
• 208000002205 allergic conjunctivitis Diseases 0.000 description 2
• 201000010105 allergic rhinitis Diseases 0.000 description 2
• 208000032775 alopecia universalis congenita Diseases 0.000 description 2
• 229960000473 altretamine Drugs 0.000 description 2
• 229960004050 aminobenzoic acid Drugs 0.000 description 2
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
• 229960003437 aminoglutethimide Drugs 0.000 description 2
• 235000011114 ammonium hydroxide Nutrition 0.000 description 2
• 208000003455 anaphylaxis Diseases 0.000 description 2
• 229940030486 androgens Drugs 0.000 description 2
• 208000007502 anemia Diseases 0.000 description 2
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
• 230000002280 anti-androgenic effect Effects 0.000 description 2
• 230000003388 anti-hormonal effect Effects 0.000 description 2
• 230000000340 anti-metabolite Effects 0.000 description 2
• 230000002785 anti-thrombosis Effects 0.000 description 2
• 239000000051 antiandrogen Substances 0.000 description 2
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
• 229940088710 antibiotic agent Drugs 0.000 description 2
• 238000011394 anticancer treatment Methods 0.000 description 2
• 229940127219 anticoagulant drug Drugs 0.000 description 2
• 239000003429 antifungal agent Substances 0.000 description 2
• 229940121375 antifungal agent Drugs 0.000 description 2
• 229940100197 antimetabolite Drugs 0.000 description 2
• 239000002256 antimetabolite Substances 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• 210000001367 artery Anatomy 0.000 description 2
• 230000002917 arthritic effect Effects 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 229940120638 avastin Drugs 0.000 description 2
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
• WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
• 230000001588 bifunctional effect Effects 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 206010006007 bone sarcoma Diseases 0.000 description 2
• 238000002725 brachytherapy Methods 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 239000000480 calcium channel blocker Substances 0.000 description 2
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 2
• 230000020411 cell activation Effects 0.000 description 2
• 238000004113 cell culture Methods 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 208000026106 cerebrovascular disease Diseases 0.000 description 2
• 229960005395 cetuximab Drugs 0.000 description 2
• 230000008859 change Effects 0.000 description 2
• 230000002113 chemopreventative effect Effects 0.000 description 2
• 230000000973 chemotherapeutic effect Effects 0.000 description 2
• 229960004630 chlorambucil Drugs 0.000 description 2
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
• 230000001886 ciliary effect Effects 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• 238000011260 co-administration Methods 0.000 description 2
• 206010009887 colitis Diseases 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 239000003086 colorant Substances 0.000 description 2
• 208000018631 connective tissue disease Diseases 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 238000013270 controlled release Methods 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 210000004087 cornea Anatomy 0.000 description 2
• 208000029078 coronary artery disease Diseases 0.000 description 2
• 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
• 230000001351 cycling effect Effects 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 239000000824 cytostatic agent Substances 0.000 description 2
• 231100000599 cytotoxic agent Toxicity 0.000 description 2
• 229960002448 dasatinib Drugs 0.000 description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
• 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 201000001981 dermatomyositis Diseases 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• BEFZAMRWPCMWFJ-UHFFFAOYSA-N desoxyepothilone A Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC=CCC1C(C)=CC1=CSC(C)=N1 BEFZAMRWPCMWFJ-UHFFFAOYSA-N 0.000 description 2
• XOZIUKBZLSUILX-UHFFFAOYSA-N desoxyepothilone B Natural products O1C(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC(C)=CCC1C(C)=CC1=CSC(C)=N1 XOZIUKBZLSUILX-UHFFFAOYSA-N 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 230000004069 differentiation Effects 0.000 description 2
• SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Chemical class CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
• 125000005879 dioxolanyl group Chemical group 0.000 description 2
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
• 239000007884 disintegrant Substances 0.000 description 2
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
• 229960003668 docetaxel Drugs 0.000 description 2
• 229960004679 doxorubicin Drugs 0.000 description 2
• 208000019479 dysautonomia Diseases 0.000 description 2
• 230000008482 dysregulation Effects 0.000 description 2
• 229940121647 egfr inhibitor Drugs 0.000 description 2
• 150000002066 eicosanoids Chemical class 0.000 description 2
• 238000005538 encapsulation Methods 0.000 description 2
• HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 description 2
• HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
• BEFZAMRWPCMWFJ-QJKGZULSSA-N epothilone C Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 BEFZAMRWPCMWFJ-QJKGZULSSA-N 0.000 description 2
• XOZIUKBZLSUILX-GIQCAXHBSA-N epothilone D Chemical compound O1C(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@@H](O)[C@@H](C)CCC\C(C)=C/C[C@H]1C(\C)=C\C1=CSC(C)=N1 XOZIUKBZLSUILX-GIQCAXHBSA-N 0.000 description 2
• 230000008029 eradication Effects 0.000 description 2
• 229940082789 erbitux Drugs 0.000 description 2
• 210000003238 esophagus Anatomy 0.000 description 2
• MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 2
• 239000003527 fibrinolytic agent Substances 0.000 description 2
• 229940126864 fibroblast growth factor Drugs 0.000 description 2
• 239000000706 filtrate Substances 0.000 description 2
• OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
• CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 2
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
• 210000003714 granulocyte Anatomy 0.000 description 2
• 150000004820 halides Chemical class 0.000 description 2
• 125000004438 haloalkoxy group Chemical group 0.000 description 2
• 125000001188 haloalkyl group Chemical group 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 208000006454 hepatitis Diseases 0.000 description 2
• 231100000283 hepatitis Toxicity 0.000 description 2
• 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
• 201000007162 hidradenitis suppurativa Diseases 0.000 description 2
• WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 2
• 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 2
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 2
• 206010020718 hyperplasia Diseases 0.000 description 2
• 230000009610 hypersensitivity Effects 0.000 description 2
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 2
• 229960001101 ifosfamide Drugs 0.000 description 2
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
• 208000009326 ileitis Diseases 0.000 description 2
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
• 208000026278 immune system disease Diseases 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 201000004653 inflammatory breast carcinoma Diseases 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 229940047122 interleukins Drugs 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 229940084651 iressa Drugs 0.000 description 2
• 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 206010024627 liposarcoma Diseases 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 201000007270 liver cancer Diseases 0.000 description 2
• 230000004807 localization Effects 0.000 description 2
• 239000007937 lozenge Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• 208000002780 macular degeneration Diseases 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 2
• 208000027202 mammary Paget disease Diseases 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 208000008585 mastocytosis Diseases 0.000 description 2
• 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 2
• 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 229960001428 mercaptopurine Drugs 0.000 description 2
• 239000002207 metabolite Substances 0.000 description 2
• GUHFNSOJOCZHQO-UHFFFAOYSA-N methyl 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate Chemical compound C1=C(C)C(C(=O)OC)=CC=C1B1OC(C)(C)C(C)(C)O1 GUHFNSOJOCZHQO-UHFFFAOYSA-N 0.000 description 2
• XSRWQTDEIOHXSL-UHFFFAOYSA-N methyl quinoline-6-carboxylate Chemical compound N1=CC=CC2=CC(C(=O)OC)=CC=C21 XSRWQTDEIOHXSL-UHFFFAOYSA-N 0.000 description 2
• 239000004005 microsphere Substances 0.000 description 2
• 229960001156 mitoxantrone Drugs 0.000 description 2
• 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 2
• 125000002757 morpholinyl group Chemical group 0.000 description 2
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
• AGEROJAJZRJBGM-UHFFFAOYSA-N n-(2-hydroxyethoxy)benzamide Chemical compound OCCONC(=O)C1=CC=CC=C1 AGEROJAJZRJBGM-UHFFFAOYSA-N 0.000 description 2
• OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 2
• 210000003739 neck Anatomy 0.000 description 2
• 208000015122 neurodegenerative disease Diseases 0.000 description 2
• 208000029974 neurofibrosarcoma Diseases 0.000 description 2
• 210000004498 neuroglial cell Anatomy 0.000 description 2
• 150000002823 nitrates Chemical class 0.000 description 2
• 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 2
• 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 2
• 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 2
• 230000002246 oncogenic effect Effects 0.000 description 2
• 102000027450 oncoproteins Human genes 0.000 description 2
• 108091008819 oncoproteins Proteins 0.000 description 2
• 201000006958 oropharynx cancer Diseases 0.000 description 2
• 201000008482 osteoarthritis Diseases 0.000 description 2
• 210000002997 osteoclast Anatomy 0.000 description 2
• 125000000160 oxazolidinyl group Chemical group 0.000 description 2
• 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 2
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
• 210000000277 pancreatic duct Anatomy 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 244000052769 pathogen Species 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 239000011574 phosphorus Substances 0.000 description 2
• 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
• 125000004193 piperazinyl group Chemical group 0.000 description 2
• 125000003386 piperidinyl group Chemical group 0.000 description 2
• 208000008423 pleurisy Diseases 0.000 description 2
• 201000000317 pneumocystosis Diseases 0.000 description 2
• 208000030428 polyarticular arthritis Diseases 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 229960004618 prednisone Drugs 0.000 description 2
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
• 208000018290 primary dysautonomia Diseases 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 150000003180 prostaglandins Chemical class 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 238000000746 purification Methods 0.000 description 2
• RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
• LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
• VXGYRCVTBHVXMZ-UHFFFAOYSA-N quinoline-6-carboxylic acid Chemical compound N1=CC=CC2=CC(C(=O)O)=CC=C21 VXGYRCVTBHVXMZ-UHFFFAOYSA-N 0.000 description 2
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 2
• 239000012857 radioactive material Substances 0.000 description 2
• 229960004622 raloxifene Drugs 0.000 description 2
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
• 208000002574 reactive arthritis Diseases 0.000 description 2
• 239000002464 receptor antagonist Substances 0.000 description 2
• 229940044551 receptor antagonist Drugs 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 206010038038 rectal cancer Diseases 0.000 description 2
• 201000001275 rectum cancer Diseases 0.000 description 2
• 238000011069 regeneration method Methods 0.000 description 2
• 206010039083 rhinitis Diseases 0.000 description 2
• 229960004641 rituximab Drugs 0.000 description 2
• 150000003873 salicylate salts Chemical class 0.000 description 2
• 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 2
• 230000001235 sensitizing effect Effects 0.000 description 2
• 229940076279 serotonin Drugs 0.000 description 2
• 230000007781 signaling event Effects 0.000 description 2
• 201000009890 sinusitis Diseases 0.000 description 2
• 229940126586 small molecule drug Drugs 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• 239000007909 solid dosage form Substances 0.000 description 2
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
• 229960000553 somatostatin Drugs 0.000 description 2
• 208000020431 spinal cord injury Diseases 0.000 description 2
• 230000007480 spreading Effects 0.000 description 2
• 238000003892 spreading Methods 0.000 description 2
• 208000017572 squamous cell neoplasm Diseases 0.000 description 2
• 238000006467 substitution reaction Methods 0.000 description 2
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• 229960001603 tamoxifen Drugs 0.000 description 2
• 230000008685 targeting Effects 0.000 description 2
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
• 230000002381 testicular Effects 0.000 description 2
• 201000003120 testicular cancer Diseases 0.000 description 2
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 125000001984 thiazolidinyl group Chemical group 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• 229960001196 thiotepa Drugs 0.000 description 2
• 206010043554 thrombocytopenia Diseases 0.000 description 2
• 150000003595 thromboxanes Chemical class 0.000 description 2
• 208000008732 thymoma Diseases 0.000 description 2
• 210000001541 thymus gland Anatomy 0.000 description 2
• 206010043778 thyroiditis Diseases 0.000 description 2
• 229960003087 tioguanine Drugs 0.000 description 2
• 208000037816 tissue injury Diseases 0.000 description 2
• 229960000187 tissue plasminogen activator Drugs 0.000 description 2
• 230000017423 tissue regeneration Effects 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
• 229960000303 topotecan Drugs 0.000 description 2
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 125000005270 trialkylamine group Chemical group 0.000 description 2
• 229910052722 tritium Inorganic materials 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 201000005112 urinary bladder cancer Diseases 0.000 description 2
• 210000002700 urine Anatomy 0.000 description 2
• 206010046766 uterine cancer Diseases 0.000 description 2
• 230000004862 vasculogenesis Effects 0.000 description 2
• 239000002525 vasculotropin inhibitor Substances 0.000 description 2
• 229940099039 velcade Drugs 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
• NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
• FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
• CHBAVXBZHKILFW-UHFFFAOYSA-N (2-methylquinolin-6-yl)methanamine Chemical compound C1=C(CN)C=CC2=NC(C)=CC=C21 CHBAVXBZHKILFW-UHFFFAOYSA-N 0.000 description 1
• WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
• FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
• KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
• DFSQCSAZKURRRE-UHFFFAOYSA-N (3,5-difluoro-4-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=C(F)C=C(B(O)O)C=C1F DFSQCSAZKURRRE-UHFFFAOYSA-N 0.000 description 1
• NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 description 1
• XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
• VYSMJCHIPNCNJL-UHFFFAOYSA-N (7-fluoroquinolin-6-yl)methanamine Chemical compound C1=CN=C2C=C(F)C(CN)=CC2=C1 VYSMJCHIPNCNJL-UHFFFAOYSA-N 0.000 description 1
• XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
• AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
• JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
• AGNGYMCLFWQVGX-AGFFZDDWSA-N (e)-1-[(2s)-2-amino-2-carboxyethoxy]-2-diazonioethenolate Chemical compound OC(=O)[C@@H](N)CO\C([O-])=C\[N+]#N AGNGYMCLFWQVGX-AGFFZDDWSA-N 0.000 description 1
• 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
• QWEWLLNSJDTOKH-UHFFFAOYSA-N 1,3-thiazole-2-carboxamide Chemical class NC(=O)C1=NC=CS1 QWEWLLNSJDTOKH-UHFFFAOYSA-N 0.000 description 1
• LFRHMTZYADABJZ-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)butan-2-amine;hydron;chloride Chemical compound Cl.CCC(N)CC1=CC=C2OCOC2=C1 LFRHMTZYADABJZ-UHFFFAOYSA-N 0.000 description 1
• QNUASQXVZJWQBW-UHFFFAOYSA-N 1-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]ethanone Chemical compound N1=CC=CC2=CC(CN3C=NC4=CC=C(N=C43)C(=O)C)=CC=C21 QNUASQXVZJWQBW-UHFFFAOYSA-N 0.000 description 1
• PDGKVEGZQSNHCO-UHFFFAOYSA-N 1-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]-n-methoxyethanimine Chemical compound C1=CN=C2C=C(F)C(CN3N=NC4=CC=C(N=C43)C(C)=NOC)=CC2=C1 PDGKVEGZQSNHCO-UHFFFAOYSA-N 0.000 description 1
• QYPDLRROIKAURY-UHFFFAOYSA-N 1-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]ethanone Chemical compound C1=CN=C2C=C(F)C(CN3N=NC4=CC=C(N=C43)C(=O)C)=CC2=C1 QYPDLRROIKAURY-UHFFFAOYSA-N 0.000 description 1
• 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
• JHLKSIOJYMGSMB-UHFFFAOYSA-N 1-bromo-3,5-difluorobenzene Chemical class FC1=CC(F)=CC(Br)=C1 JHLKSIOJYMGSMB-UHFFFAOYSA-N 0.000 description 1
• 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
• GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
• DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 description 1
• SXFWKZNLYYRHMK-UHFFFAOYSA-N 1h-indolo[7,6-f]quinoline Chemical class C1=CC=C2C3=C(NC=C4)C4=CC=C3C=CC2=N1 SXFWKZNLYYRHMK-UHFFFAOYSA-N 0.000 description 1
• BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
• JLZVIWSFUPLSOR-UHFFFAOYSA-N 2,3-difluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1F JLZVIWSFUPLSOR-UHFFFAOYSA-N 0.000 description 1
• RTXYIHGMYDJHEU-UHFFFAOYSA-N 2,4-dichloro-3-nitropyridine Chemical compound [O-][N+](=O)C1=C(Cl)C=CN=C1Cl RTXYIHGMYDJHEU-UHFFFAOYSA-N 0.000 description 1
• BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
• GSZDBQKZAWFMIC-UHFFFAOYSA-N 2,6-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC(F)=C(C(N)=O)C(F)=C1 GSZDBQKZAWFMIC-UHFFFAOYSA-N 0.000 description 1
• VJMMFYVVVXIXDH-UHFFFAOYSA-N 2,6-difluoro-4-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(F)C(C(=O)N)=C(F)C=C1C1=CC=C(N=CN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 VJMMFYVVVXIXDH-UHFFFAOYSA-N 0.000 description 1
• OAYOVBXHLNEPOD-UHFFFAOYSA-N 2-(1,3-benzothiazol-6-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2N=CSC2=C1 OAYOVBXHLNEPOD-UHFFFAOYSA-N 0.000 description 1
• 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
• JWZUQQMOZJJQHC-UHFFFAOYSA-N 2-[[2-chloro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]phenyl]methylamino]ethyl acetate Chemical compound C(C)(=O)OCCNCC1=C(C=C(C=C1)C1=CC=C2C(=N1)N(N=N2)CC=2C=C1C=CC=NC1=CC2)Cl JWZUQQMOZJJQHC-UHFFFAOYSA-N 0.000 description 1
• VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
• QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
• WWWTWPXKLJTKPM-UHFFFAOYSA-N 2-aminooxyethanol Chemical compound NOCCO WWWTWPXKLJTKPM-UHFFFAOYSA-N 0.000 description 1
• 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
• YNSWRTOFHHWQSU-UHFFFAOYSA-N 2-chloro-4-[3-(1-quinolin-6-ylethyl)imidazo[4,5-b]pyridin-5-yl]benzamide Chemical compound C=1C=C2N=CC=CC2=CC=1C(C)N(C1=N2)C=NC1=CC=C2C1=CC=C(C(N)=O)C(Cl)=C1 YNSWRTOFHHWQSU-UHFFFAOYSA-N 0.000 description 1
• JBLIPQDYRNUBON-UHFFFAOYSA-N 2-chloro-4-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]benzoic acid Chemical compound C1=C(Cl)C(C(=O)O)=CC=C1C1=CC=C(N=CN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 JBLIPQDYRNUBON-UHFFFAOYSA-N 0.000 description 1
• ZZCCKJHSWHWFKZ-UHFFFAOYSA-N 2-chloro-4-[3-[(2-methylquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]benzoic acid Chemical compound C1=CC2=NC(C)=CC=C2C=C1CN(C1=N2)N=NC1=CC=C2C1=CC=C(C(O)=O)C(Cl)=C1 ZZCCKJHSWHWFKZ-UHFFFAOYSA-N 0.000 description 1
• FDAYLTPAFBGXAB-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)ethanamine Chemical compound ClCCN(CCCl)CCCl FDAYLTPAFBGXAB-UHFFFAOYSA-N 0.000 description 1
• VNBAOSVONFJBKP-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)propan-1-amine;hydrochloride Chemical compound Cl.CC(Cl)CN(CCCl)CCCl VNBAOSVONFJBKP-UHFFFAOYSA-N 0.000 description 1
• FNKXNXPJOSVBDG-UHFFFAOYSA-N 2-chloro-n-(2-hydroxyethoxy)-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzamide;hydrobromide Chemical compound Br.C1=C(Cl)C(C(=O)NOCCO)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 FNKXNXPJOSVBDG-UHFFFAOYSA-N 0.000 description 1
• ITXNDDPDABTCBO-UHFFFAOYSA-N 2-chloro-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1Cl ITXNDDPDABTCBO-UHFFFAOYSA-N 0.000 description 1
• 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
• 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
• MZJPXQGWYNZKJS-UHFFFAOYSA-N 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide Chemical compound C1=C(C(N)=O)C(C)=CC(B2OC(C)(C)C(C)(C)O2)=C1 MZJPXQGWYNZKJS-UHFFFAOYSA-N 0.000 description 1
• IZONZQFTYGVOOO-UHFFFAOYSA-N 2-methylquinoline-6-carboxylic acid Chemical compound C1=C(C(O)=O)C=CC2=NC(C)=CC=C21 IZONZQFTYGVOOO-UHFFFAOYSA-N 0.000 description 1
• DTIBHJPQXHCTBV-UHFFFAOYSA-N 2-n-(1,3-benzothiazol-6-ylmethyl)-6-chloropyridine-2,3-diamine Chemical compound NC1=CC=C(Cl)N=C1NCC1=CC=C(N=CS2)C2=C1 DTIBHJPQXHCTBV-UHFFFAOYSA-N 0.000 description 1
• 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
• KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical class OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
• 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
• ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
• NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 1
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
• SOFRHZUTPGJWAM-UHFFFAOYSA-N 3-hydroxy-4-[(2-methoxy-5-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound COc1ccc(cc1N=Nc1c(O)c(cc2ccccc12)C(=O)Nc1cccc(c1)[N+]([O-])=O)[N+]([O-])=O SOFRHZUTPGJWAM-UHFFFAOYSA-N 0.000 description 1
• BPYHGTCRXDWOIQ-UHFFFAOYSA-N 3-nitropyridin-2-amine Chemical compound NC1=NC=CC=C1[N+]([O-])=O BPYHGTCRXDWOIQ-UHFFFAOYSA-N 0.000 description 1
• QLILRKBRWXALIE-UHFFFAOYSA-N 3-nitropyridine Chemical compound [O-][N+](=O)C1=CC=CN=C1 QLILRKBRWXALIE-UHFFFAOYSA-N 0.000 description 1
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
• DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
• DANLZOIRUUHIIX-UHFFFAOYSA-N 4-[1-[2-chloro-6-(trifluoromethyl)benzoyl]indazol-3-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C(C1=CC=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C(F)(F)F DANLZOIRUUHIIX-UHFFFAOYSA-N 0.000 description 1
• YTSVFNKFFXRFCG-UHFFFAOYSA-N 4-[3-(1,3-benzothiazol-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]-2,6-difluorobenzoic acid Chemical compound C1=C(F)C(C(=O)O)=C(F)C=C1C1=CC=C(N=NN2CC=3C=C4SC=NC4=CC=3)C2=N1 YTSVFNKFFXRFCG-UHFFFAOYSA-N 0.000 description 1
• AMYVXCDQUIDSGJ-UHFFFAOYSA-N 4-[3-(1,3-benzothiazol-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]-2-chlorobenzoic acid Chemical compound C1=C(Cl)C(C(=O)O)=CC=C1C1=CC=C(N=NN2CC=3C=C4SC=NC4=CC=3)C2=N1 AMYVXCDQUIDSGJ-UHFFFAOYSA-N 0.000 description 1
• AJCHMVUCQUVBIF-UHFFFAOYSA-N 4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 AJCHMVUCQUVBIF-UHFFFAOYSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• NLPWSMKACWGINL-UHFFFAOYSA-N 4-azido-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1O NLPWSMKACWGINL-UHFFFAOYSA-N 0.000 description 1
• CZGVAISJIQNQEJ-UHFFFAOYSA-N 4-bromo-2,6-difluorobenzaldehyde Chemical compound FC1=CC(Br)=CC(F)=C1C=O CZGVAISJIQNQEJ-UHFFFAOYSA-N 0.000 description 1
• IRHPJGPQWZEZRX-UHFFFAOYSA-N 4-bromo-2,6-difluorobenzoic acid Chemical compound OC(=O)C1=C(F)C=C(Br)C=C1F IRHPJGPQWZEZRX-UHFFFAOYSA-N 0.000 description 1
• UFLXVXIDMCMCCF-UHFFFAOYSA-N 4-bromo-2-chloro-n-methylbenzamide Chemical compound CNC(=O)C1=CC=C(Br)C=C1Cl UFLXVXIDMCMCCF-UHFFFAOYSA-N 0.000 description 1
• ORFWVGHYCXGUHS-UHFFFAOYSA-N 4-bromo-2-chlorobenzamide Chemical compound NC(=O)C1=CC=C(Br)C=C1Cl ORFWVGHYCXGUHS-UHFFFAOYSA-N 0.000 description 1
• JAVZWSOFJKYSDY-UHFFFAOYSA-N 4-bromo-2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1Cl JAVZWSOFJKYSDY-UHFFFAOYSA-N 0.000 description 1
• POILWHVDKZOXJZ-UHFFFAOYSA-N 4-hydroxypent-3-en-2-one Chemical compound CC(O)=CC(C)=O POILWHVDKZOXJZ-UHFFFAOYSA-N 0.000 description 1
• BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
• IRTWLWBEQPMVNM-UHFFFAOYSA-N 5,7-difluoroquinoline Chemical compound C1=CC=NC2=CC(F)=CC(F)=C21 IRTWLWBEQPMVNM-UHFFFAOYSA-N 0.000 description 1
• IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• SJVGFKBLUYAEOK-SFHVURJKSA-N 6-[4-[(3S)-3-(3,5-difluorophenyl)-3,4-dihydropyrazole-2-carbonyl]piperidin-1-yl]pyrimidine-4-carbonitrile Chemical compound FC=1C=C(C=C(C=1)F)[C@@H]1CC=NN1C(=O)C1CCN(CC1)C1=CC(=NC=N1)C#N SJVGFKBLUYAEOK-SFHVURJKSA-N 0.000 description 1
• WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
• VYBCOTBIQJEOQU-UHFFFAOYSA-N 6-chloro-2-n-[(7-fluoroquinolin-6-yl)methyl]pyridine-2,3-diamine Chemical compound NC1=CC=C(Cl)N=C1NCC1=CC2=CC=CN=C2C=C1F VYBCOTBIQJEOQU-UHFFFAOYSA-N 0.000 description 1
• CUYTVUZFOSBVKK-UHFFFAOYSA-N 6-chloro-3-nitro-n-(quinolin-6-ylmethyl)pyridin-2-amine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1NCC1=CC=C(N=CC=C2)C2=C1 CUYTVUZFOSBVKK-UHFFFAOYSA-N 0.000 description 1
• CQKPXWPKOSBOIO-UHFFFAOYSA-N 6-chloro-n-[(2-methylquinolin-6-yl)methyl]-3-nitropyridin-2-amine Chemical compound C1=CC2=NC(C)=CC=C2C=C1CNC1=NC(Cl)=CC=C1[N+]([O-])=O CQKPXWPKOSBOIO-UHFFFAOYSA-N 0.000 description 1
• 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
• YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
• ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
• HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
• 239000005541 ACE inhibitor Substances 0.000 description 1
• 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
• 208000002874 Acne Vulgaris Diseases 0.000 description 1
• 206010000599 Acromegaly Diseases 0.000 description 1
• 206010000830 Acute leukaemia Diseases 0.000 description 1
• 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 206010058284 Allergy to arthropod sting Diseases 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 206010001889 Alveolitis Diseases 0.000 description 1
• 101500009173 Amanita phalloides Cycloamanide B Proteins 0.000 description 1
• 208000004881 Amebiasis Diseases 0.000 description 1
• 206010001935 American trypanosomiasis Diseases 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 206010060937 Amniotic cavity infection Diseases 0.000 description 1
• 206010001980 Amoebiasis Diseases 0.000 description 1
• 241000272522 Anas Species 0.000 description 1
• 206010002329 Aneurysm Diseases 0.000 description 1
• 206010002383 Angina Pectoris Diseases 0.000 description 1
• 208000028185 Angioedema Diseases 0.000 description 1
• 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 1
• 102000009840 Angiopoietins Human genes 0.000 description 1
• 108010009906 Angiopoietins Proteins 0.000 description 1
• 108010064733 Angiotensins Proteins 0.000 description 1
• 102000015427 Angiotensins Human genes 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 101001010152 Aplysia californica Probable glutathione transferase Proteins 0.000 description 1
• 206010003011 Appendicitis Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 102000014654 Aromatase Human genes 0.000 description 1
• 108010078554 Aromatase Proteins 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 206010003557 Asthma exercise induced Diseases 0.000 description 1
• 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
• 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
• 108010081589 Becaplermin Proteins 0.000 description 1
• 208000027496 Behcet disease Diseases 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• 208000035821 Benign schwannoma Diseases 0.000 description 1
• VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
• 206010058956 Bicytopenia Diseases 0.000 description 1
• 206010004659 Biliary cirrhosis Diseases 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 101800004538 Bradykinin Proteins 0.000 description 1
• 206010006143 Brain stem glioma Diseases 0.000 description 1
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
• 206010006448 Bronchiolitis Diseases 0.000 description 1
• 206010006458 Bronchitis chronic Diseases 0.000 description 1
• 206010006811 Bursitis Diseases 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• KPZFPSGMZVNTMR-UHFFFAOYSA-N COC(=O)c1ccc(cc1Cl)-c1ccc2nnn(Cc3ccc4ncsc4c3)c2n1 Chemical compound COC(=O)c1ccc(cc1Cl)-c1ccc2nnn(Cc3ccc4ncsc4c3)c2n1 KPZFPSGMZVNTMR-UHFFFAOYSA-N 0.000 description 1
• 108060001064 Calcitonin Proteins 0.000 description 1
• 102400000113 Calcitonin Human genes 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• 206010058019 Cancer Pain Diseases 0.000 description 1
• 239000005461 Canertinib Substances 0.000 description 1
• 241000282472 Canis lupus familiaris Species 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
• SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
• 206010007556 Cardiac failure acute Diseases 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 102000053642 Catalytic RNA Human genes 0.000 description 1
• 108090000994 Catalytic RNA Proteins 0.000 description 1
• 241000700198 Cavia Species 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 229930186147 Cephalosporin Natural products 0.000 description 1
• 208000024699 Chagas disease Diseases 0.000 description 1
• 108010008951 Chemokine CXCL12 Proteins 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• XCDXSSFOJZZGQC-UHFFFAOYSA-N Chlornaphazine Chemical compound C1=CC=CC2=CC(N(CCCl)CCCl)=CC=C21 XCDXSSFOJZZGQC-UHFFFAOYSA-N 0.000 description 1
• MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 201000009047 Chordoma Diseases 0.000 description 1
• 208000008158 Chorioamnionitis Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• 206010053567 Coagulopathies Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 206010056489 Coronary artery restenosis Diseases 0.000 description 1
• 102400000739 Corticotropin Human genes 0.000 description 1
• 101800000414 Corticotropin Proteins 0.000 description 1
• 208000009798 Craniopharyngioma Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
• 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
• 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
• 229930105110 Cyclosporin A Natural products 0.000 description 1
• 108010036949 Cyclosporine Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
• 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
• 206010011841 Dacryoadenitis acquired Diseases 0.000 description 1
• WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
• 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
• NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 206010051392 Diapedesis Diseases 0.000 description 1
• 206010012735 Diarrhoea Diseases 0.000 description 1
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
• 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
• 208000006402 Ductal Carcinoma Diseases 0.000 description 1
• 208000032928 Dyslipidaemia Diseases 0.000 description 1
• 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 208000004145 Endometritis Diseases 0.000 description 1
• 101800004490 Endothelin-1 Proteins 0.000 description 1
• 102400000686 Endothelin-1 Human genes 0.000 description 1
• SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
• 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 1
• 201000011275 Epicondylitis Diseases 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
• OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
• QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 description 1
• BEFZAMRWPCMWFJ-JRBBLYSQSA-N Epothilone C Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C=C\C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C BEFZAMRWPCMWFJ-JRBBLYSQSA-N 0.000 description 1
• XOZIUKBZLSUILX-SDMHVBBESA-N Epothilone D Natural products O=C1[C@H](C)[C@@H](O)[C@@H](C)CCC/C(/C)=C/C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C XOZIUKBZLSUILX-SDMHVBBESA-N 0.000 description 1
• 241000283086 Equidae Species 0.000 description 1
• 208000010228 Erectile Dysfunction Diseases 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 206010015218 Erythema multiforme Diseases 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 102000003951 Erythropoietin Human genes 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 229930189413 Esperamicin Natural products 0.000 description 1
• 108010008165 Etanercept Proteins 0.000 description 1
• BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
• JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
• 206010016228 Fasciitis Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
• 102100028412 Fibroblast growth factor 10 Human genes 0.000 description 1
• 108090001047 Fibroblast growth factor 10 Proteins 0.000 description 1
• 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 1
• 102000003969 Fibroblast growth factor 4 Human genes 0.000 description 1
• 102000003967 Fibroblast growth factor 5 Human genes 0.000 description 1
• 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
• 102000003968 Fibroblast growth factor 6 Human genes 0.000 description 1
• 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 1
• 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 1
• 108090000367 Fibroblast growth factor 9 Proteins 0.000 description 1
• 208000001640 Fibromyalgia Diseases 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
• 208000004262 Food Hypersensitivity Diseases 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
• 241000287828 Gallus gallus Species 0.000 description 1
• 102400000921 Gastrin Human genes 0.000 description 1
• 108010052343 Gastrins Proteins 0.000 description 1
• 208000005577 Gastroenteritis Diseases 0.000 description 1
• 208000018522 Gastrointestinal disease Diseases 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 208000021309 Germ cell tumor Diseases 0.000 description 1
• 206010018258 Giant papillary conjunctivitis Diseases 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
• 206010018404 Glucagonoma Diseases 0.000 description 1
• 108010024636 Glutathione Proteins 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 201000005569 Gout Diseases 0.000 description 1
• 206010018634 Gouty Arthritis Diseases 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
• 208000001204 Hashimoto Disease Diseases 0.000 description 1
• 206010019280 Heart failures Diseases 0.000 description 1
• 208000006968 Helminthiasis Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 208000005176 Hepatitis C Diseases 0.000 description 1
• 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
• 108010072039 Histidine kinase Proteins 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 1
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
• 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 1
• 101001052849 Homo sapiens Tyrosine-protein kinase Fer Proteins 0.000 description 1
• 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• 206010021042 Hypopharyngeal cancer Diseases 0.000 description 1
• 206010056305 Hypopharyngeal neoplasm Diseases 0.000 description 1
• 208000001953 Hypotension Diseases 0.000 description 1
• 206010021138 Hypovolaemic shock Diseases 0.000 description 1
• MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
• 206010053574 Immunoblastic lymphoma Diseases 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 208000029462 Immunodeficiency disease Diseases 0.000 description 1
• 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
• 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
• 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 108010002386 Interleukin-3 Proteins 0.000 description 1
• 108010002616 Interleukin-5 Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 108090001007 Interleukin-8 Proteins 0.000 description 1
• 102000004890 Interleukin-8 Human genes 0.000 description 1
• 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
• 206010073086 Iris melanoma Diseases 0.000 description 1
• 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
• 206010023330 Keloid scar Diseases 0.000 description 1
• 102100035792 Kininogen-1 Human genes 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• 150000000994 L-ascorbates Chemical class 0.000 description 1
• LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• 201000008197 Laryngitis Diseases 0.000 description 1
• 208000004554 Leishmaniasis Diseases 0.000 description 1
• 229920001491 Lentinan Polymers 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 102000004058 Leukemia inhibitory factor Human genes 0.000 description 1
• 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
• 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 1
• 101710142062 Leukemia inhibitory factor receptor Proteins 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• 201000004462 Leydig Cell Tumor Diseases 0.000 description 1
• 208000017170 Lipid metabolism disease Diseases 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 208000019693 Lung disease Diseases 0.000 description 1
• 208000005777 Lupus Nephritis Diseases 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 206010025312 Lymphoma AIDS related Diseases 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 229940125895 MET kinase inhibitor Drugs 0.000 description 1
• 229940124761 MMP inhibitor Drugs 0.000 description 1
• 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
• 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
• 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
• 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
• 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 1
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
• SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
• 208000007054 Medullary Carcinoma Diseases 0.000 description 1
• 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 206010027193 Meningioma malignant Diseases 0.000 description 1
• IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• 101710161855 Methionine aminopeptidase 1 Proteins 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
• 238000006845 Michael addition reaction Methods 0.000 description 1
• VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
• 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
• 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 101710103983 Modulator of apoptosis 1 Proteins 0.000 description 1
• UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
• 208000003445 Mouth Neoplasms Diseases 0.000 description 1
• 206010073101 Mucinous breast carcinoma Diseases 0.000 description 1
• 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
• 101100268648 Mus musculus Abl1 gene Proteins 0.000 description 1
• 101100216078 Mus musculus Ang4 gene Proteins 0.000 description 1
• 101100346764 Mus musculus Mtln gene Proteins 0.000 description 1
• 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 1
• 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
• 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
• 208000000112 Myalgia Diseases 0.000 description 1
• 101001013152 Mycobacterium avium Major membrane protein 1 Proteins 0.000 description 1
• 101001013151 Mycobacterium leprae (strain TN) Major membrane protein I Proteins 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 208000003926 Myelitis Diseases 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 210000004460 N cell Anatomy 0.000 description 1
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
• OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
• LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
• BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
• 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
• 206010028813 Nausea Diseases 0.000 description 1
• 206010051606 Necrotising colitis Diseases 0.000 description 1
• 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
• 206010029113 Neovascularisation Diseases 0.000 description 1
• 108010025020 Nerve Growth Factor Proteins 0.000 description 1
• 102000015336 Nerve Growth Factor Human genes 0.000 description 1
• 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
• 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 208000009905 Neurofibromatoses Diseases 0.000 description 1
• 102100026379 Neurofibromin Human genes 0.000 description 1
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
• 108090000742 Neurotrophin 3 Proteins 0.000 description 1
• 102100029268 Neurotrophin-3 Human genes 0.000 description 1
• 102100030411 Neutrophil collagenase Human genes 0.000 description 1
• 101710118230 Neutrophil collagenase Proteins 0.000 description 1
• SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
• 206010029488 Nodular melanoma Diseases 0.000 description 1
• KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
• 229910004679 ONO2 Inorganic materials 0.000 description 1
• 208000022873 Ocular disease Diseases 0.000 description 1
• 229930187135 Olivomycin Natural products 0.000 description 1
• 206010053854 Opsoclonus myoclonus Diseases 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 206010031149 Osteitis Diseases 0.000 description 1
• 208000005141 Otitis Diseases 0.000 description 1
• 206010033078 Otitis media Diseases 0.000 description 1
• 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
• 206010053869 POEMS syndrome Diseases 0.000 description 1
• 208000016222 Pancreatic disease Diseases 0.000 description 1
• 206010033661 Pancytopenia Diseases 0.000 description 1
• 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
• 102000003982 Parathyroid hormone Human genes 0.000 description 1
• 108090000445 Parathyroid hormone Proteins 0.000 description 1
• 208000018737 Parkinson disease Diseases 0.000 description 1
• 206010034038 Parotitis Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• 108010057150 Peplomycin Proteins 0.000 description 1
• 208000008469 Peptic Ulcer Diseases 0.000 description 1
• 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
• 201000007100 Pharyngitis Diseases 0.000 description 1
• 241000286209 Phasianidae Species 0.000 description 1
• 206010050487 Pinealoblastoma Diseases 0.000 description 1
• KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
• 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
• 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
• 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
• 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
• 101710164680 Platelet-derived growth factor receptor beta Proteins 0.000 description 1
• 101710103506 Platelet-derived growth factor subunit A Proteins 0.000 description 1
• 102100037596 Platelet-derived growth factor subunit A Human genes 0.000 description 1
• 101710103494 Platelet-derived growth factor subunit B Proteins 0.000 description 1
• 102100040990 Platelet-derived growth factor subunit B Human genes 0.000 description 1
• 206010035742 Pneumonitis Diseases 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 239000004372 Polyvinyl alcohol Substances 0.000 description 1
• HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
• 208000007541 Preleukemia Diseases 0.000 description 1
• 206010036774 Proctitis Diseases 0.000 description 1
• 102000003946 Prolactin Human genes 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
• 101710151715 Protein 7 Proteins 0.000 description 1
• 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
• 208000010362 Protozoan Infections Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 206010037596 Pyelonephritis Diseases 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• GIIWGCBLYNDKBO-UHFFFAOYSA-N Quinoline 1-oxide Chemical compound C1=CC=C2[N+]([O-])=CC=CC2=C1 GIIWGCBLYNDKBO-UHFFFAOYSA-N 0.000 description 1
• AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 101500026849 Rattus norvegicus C3a anaphylatoxin Proteins 0.000 description 1
• 101100130647 Rattus norvegicus Mmp7 gene Proteins 0.000 description 1
• 102100028255 Renin Human genes 0.000 description 1
• 108090000783 Renin Proteins 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 241000219061 Rheum Species 0.000 description 1
• 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
• 206010061934 Salivary gland cancer Diseases 0.000 description 1
• 208000007893 Salpingitis Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• XHQYBDSXTDXSHY-UHFFFAOYSA-N Semicarbazide hydrochloride Chemical compound Cl.NNC(N)=O XHQYBDSXTDXSHY-UHFFFAOYSA-N 0.000 description 1
• 208000003274 Sertoli cell tumor Diseases 0.000 description 1
• 201000010001 Silicosis Diseases 0.000 description 1
• 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
• 229920000519 Sizofiran Polymers 0.000 description 1
• 208000021386 Sjogren Syndrome Diseases 0.000 description 1
• 206010058141 Skin graft rejection Diseases 0.000 description 1
• 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
• 208000004346 Smoldering Multiple Myeloma Diseases 0.000 description 1
• 108010017622 Somatomedin Receptors Proteins 0.000 description 1
• 102000004584 Somatomedin Receptors Human genes 0.000 description 1
• 201000002661 Spondylitis Diseases 0.000 description 1
• 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
• 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
• 108010023197 Streptokinase Proteins 0.000 description 1
• 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
• 102100030416 Stromelysin-1 Human genes 0.000 description 1
• 101710108790 Stromelysin-1 Proteins 0.000 description 1
• 102100028848 Stromelysin-2 Human genes 0.000 description 1
• 101710108792 Stromelysin-2 Proteins 0.000 description 1
• 102100028847 Stromelysin-3 Human genes 0.000 description 1
• 108050005271 Stromelysin-3 Proteins 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• 241000282887 Suidae Species 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
• 206010042674 Swelling Diseases 0.000 description 1
• 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
• 239000000150 Sympathomimetic Substances 0.000 description 1
• 208000000389 T-cell leukemia Diseases 0.000 description 1
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
• 229940123237 Taxane Drugs 0.000 description 1
• 208000000491 Tendinopathy Diseases 0.000 description 1
• 206010043255 Tendonitis Diseases 0.000 description 1
• 206010043276 Teratoma Diseases 0.000 description 1
• JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
• 229910052776 Thorium Inorganic materials 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 102000036693 Thrombopoietin Human genes 0.000 description 1
• 108010041111 Thrombopoietin Proteins 0.000 description 1
• 102100031372 Thymidine phosphorylase Human genes 0.000 description 1
• 108700023160 Thymidine phosphorylases Proteins 0.000 description 1
• 208000000728 Thymus Neoplasms Diseases 0.000 description 1
• DQHNAVOVODVIMG-UHFFFAOYSA-M Tiotropium bromide Chemical compound [Br-].C1C(C2C3O2)[N+](C)(C)C3CC1OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DQHNAVOVODVIMG-UHFFFAOYSA-M 0.000 description 1
• 208000026062 Tissue disease Diseases 0.000 description 1
• 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
• 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
• IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
• 206010044248 Toxic shock syndrome Diseases 0.000 description 1
• 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
• 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
• 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
• 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
• 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
• 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
• 208000030886 Traumatic Brain injury Diseases 0.000 description 1
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
• 208000005448 Trichomonas Infections Diseases 0.000 description 1
• 206010044620 Trichomoniasis Diseases 0.000 description 1
• UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
• APJYDQYYACXCRM-UHFFFAOYSA-N Tryptamine Natural products C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 1
• 206010073104 Tubular breast carcinoma Diseases 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
• 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
• 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
• 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
• 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
• 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
• 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
• 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 208000006374 Uterine Cervicitis Diseases 0.000 description 1
• 208000009311 VIPoma Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 206010053648 Vascular occlusion Diseases 0.000 description 1
• 206010057469 Vascular stenosis Diseases 0.000 description 1
• GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
• 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
• 108010004977 Vasopressins Proteins 0.000 description 1
• 102000002852 Vasopressins Human genes 0.000 description 1
• 208000014070 Vestibular schwannoma Diseases 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 229930003316 Vitamin D Natural products 0.000 description 1
• QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
• 206010047700 Vomiting Diseases 0.000 description 1
• 206010047741 Vulval cancer Diseases 0.000 description 1
• 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
• 208000012018 Yolk sac tumor Diseases 0.000 description 1
• ZYVSOIYQKUDENJ-ASUJBHBQSA-N [(2R,3R,4R,6R)-6-[[(6S,7S)-6-[(2S,4R,5R,6R)-4-[(2R,4R,5R,6R)-4-[(2S,4S,5S,6S)-5-acetyloxy-4-hydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-7-[(3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-4,10-dihydroxy-3-methyl-5-oxo-7,8-dihydro-6H-anthracen-2-yl]oxy]-4-[(2R,4R,5R,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-2-methyloxan-3-yl] acetate Chemical class COC([C@@H]1Cc2cc3cc(O[C@@H]4C[C@@H](O[C@@H]5C[C@@H](O)[C@@H](OC)[C@@H](C)O5)[C@H](OC(C)=O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@@H](OC(C)=O)[C@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O ZYVSOIYQKUDENJ-ASUJBHBQSA-N 0.000 description 1
• SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
• YYAZJTUGSQOFHG-IAVNQIGZSA-N [(6s,8s,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]eth Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)C1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-IAVNQIGZSA-N 0.000 description 1
• IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
• IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
• XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
• JSTADIGKFYFAIY-GJNDDOAHSA-K [2-[bis[[hydroxy(oxido)phosphoryl]methyl]amino]ethyl-(phosphonomethyl)amino]methyl-hydroxyphosphinate;samarium-153(3+) Chemical compound [H+].[H+].[H+].[H+].[H+].[153Sm+3].[O-]P([O-])(=O)CN(CP([O-])([O-])=O)CCN(CP([O-])([O-])=O)CP([O-])([O-])=O JSTADIGKFYFAIY-GJNDDOAHSA-K 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
• 229950002684 aceglatone Drugs 0.000 description 1
• 229940022663 acetate Drugs 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 206010000496 acne Diseases 0.000 description 1
• 208000017733 acquired polycythemia vera Diseases 0.000 description 1
• 206010000583 acral lentiginous melanoma Diseases 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 208000009621 actinic keratosis Diseases 0.000 description 1
• 229910052767 actinium Inorganic materials 0.000 description 1
• QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 1
• 229930183665 actinomycin Natural products 0.000 description 1
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 231100000851 acute glomerulonephritis Toxicity 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000000996 additive effect Effects 0.000 description 1
• 238000009098 adjuvant therapy Methods 0.000 description 1
• 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
• 201000005188 adrenal gland cancer Diseases 0.000 description 1
• 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
• 230000001800 adrenalinergic effect Effects 0.000 description 1
• 239000000048 adrenergic agonist Substances 0.000 description 1
• 239000000674 adrenergic antagonist Substances 0.000 description 1
• 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
• 229940009456 adriamycin Drugs 0.000 description 1
• 201000006966 adult T-cell leukemia Diseases 0.000 description 1
• 229940090167 advair Drugs 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• 229960003767 alanine Drugs 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 208000002353 alcoholic hepatitis Diseases 0.000 description 1
• IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
• 229960000548 alemtuzumab Drugs 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
• 150000008052 alkyl sulfonates Chemical class 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 208000002029 allergic contact dermatitis Diseases 0.000 description 1
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• LBDSXVIYZYSRII-IGMARMGPSA-N alpha-particle Chemical compound [4He+2] LBDSXVIYZYSRII-IGMARMGPSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229940126575 aminoglycoside Drugs 0.000 description 1
• 229960002749 aminolevulinic acid Drugs 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 150000003863 ammonium salts Chemical class 0.000 description 1
• 229960001220 amsacrine Drugs 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 206010002224 anaplastic astrocytoma Diseases 0.000 description 1
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
• 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
• BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
• 229950000242 ancitabine Drugs 0.000 description 1
• 238000002399 angioplasty Methods 0.000 description 1
• 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
• 150000008064 anhydrides Chemical class 0.000 description 1
• 230000001772 anti-angiogenic effect Effects 0.000 description 1
• 238000011122 anti-angiogenic therapy Methods 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000003474 anti-emetic effect Effects 0.000 description 1
• 229940046836 anti-estrogen Drugs 0.000 description 1
• 230000001833 anti-estrogenic effect Effects 0.000 description 1
• 229940124599 anti-inflammatory drug Drugs 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000002001 anti-metastasis Effects 0.000 description 1
• 230000000118 anti-neoplastic effect Effects 0.000 description 1
• 230000000702 anti-platelet effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 239000003173 antianemic agent Substances 0.000 description 1
• 239000002111 antiemetic agent Substances 0.000 description 1
• 229940125683 antiemetic agent Drugs 0.000 description 1
• 239000013059 antihormonal agent Substances 0.000 description 1
• 239000002220 antihypertensive agent Substances 0.000 description 1
• 229940030600 antihypertensive agent Drugs 0.000 description 1
• 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
• 239000004599 antimicrobial Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
• 229940127218 antiplatelet drug Drugs 0.000 description 1
• 239000002221 antipyretic Substances 0.000 description 1
• 229940125716 antipyretic agent Drugs 0.000 description 1
• 229940124522 antiretrovirals Drugs 0.000 description 1
• 239000003903 antiretrovirus agent Substances 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 229960004676 antithrombotic agent Drugs 0.000 description 1
• 239000003200 antithyroid agent Substances 0.000 description 1
• 229940043671 antithyroid preparations Drugs 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 150000008209 arabinosides Chemical class 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
• 229940078010 arimidex Drugs 0.000 description 1
• 230000006793 arrhythmia Effects 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 206010003230 arteritis Diseases 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 206010069664 atopic keratoconjunctivitis Diseases 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 239000005667 attractant Substances 0.000 description 1
• 230000003190 augmentative effect Effects 0.000 description 1
• 239000005441 aurora Substances 0.000 description 1
• 210000003192 autonomic ganglia Anatomy 0.000 description 1
• 230000035578 autophosphorylation Effects 0.000 description 1
• 229940003504 avonex Drugs 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 229950011321 azaserine Drugs 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• 125000002785 azepinyl group Chemical group 0.000 description 1
• 125000002393 azetidinyl group Chemical group 0.000 description 1
• 150000001541 aziridines Chemical class 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 208000003373 basosquamous carcinoma Diseases 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
• 229960000397 bevacizumab Drugs 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 238000010256 biochemical assay Methods 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 239000012620 biological material Substances 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 230000036983 biotransformation Effects 0.000 description 1
• 239000004305 biphenyl Substances 0.000 description 1
• 235000010290 biphenyl Nutrition 0.000 description 1
• 229950008548 bisantrene Drugs 0.000 description 1
• 210000001109 blastomere Anatomy 0.000 description 1
• 208000010217 blepharitis Diseases 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 230000036765 blood level Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 208000018420 bone fibrosarcoma Diseases 0.000 description 1
• 208000018339 bone inflammation disease Diseases 0.000 description 1
• 238000010322 bone marrow transplantation Methods 0.000 description 1
• 230000008416 bone turnover Effects 0.000 description 1
• 150000001642 boronic acid derivatives Chemical class 0.000 description 1
• 229960001467 bortezomib Drugs 0.000 description 1
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
• 239000003152 bradykinin antagonist Substances 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
• 201000007476 breast mucinous carcinoma Diseases 0.000 description 1
• 201000000135 breast papillary carcinoma Diseases 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 201000009267 bronchiectasis Diseases 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 108700002839 cactinomycin Proteins 0.000 description 1
• 229950009908 cactinomycin Drugs 0.000 description 1
• 230000002308 calcification Effects 0.000 description 1
• BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
• 229960004015 calcitonin Drugs 0.000 description 1
• HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
• 229930195731 calicheamicin Natural products 0.000 description 1
• 229950009823 calusterone Drugs 0.000 description 1
• IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• 229950002826 canertinib Drugs 0.000 description 1
• OMZCMEYTWSXEPZ-UHFFFAOYSA-N canertinib Chemical compound C1=C(Cl)C(F)=CC=C1NC1=NC=NC2=CC(OCCCN3CCOCC3)=C(NC(=O)C=C)C=C12 OMZCMEYTWSXEPZ-UHFFFAOYSA-N 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 229960002115 carboquone Drugs 0.000 description 1
• XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
• 229930188550 carminomycin Natural products 0.000 description 1
• XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
• 229960003261 carmofur Drugs 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 229950001725 carubicin Drugs 0.000 description 1
• 108010047060 carzinophilin Proteins 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 150000003943 catecholamines Chemical class 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000036978 cell physiology Effects 0.000 description 1
• 108091092328 cellular RNA Proteins 0.000 description 1
• 230000030570 cellular localization Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 201000007455 central nervous system cancer Diseases 0.000 description 1
• 229940124587 cephalosporin Drugs 0.000 description 1
• 150000001780 cephalosporins Chemical class 0.000 description 1
• 208000025434 cerebellar degeneration Diseases 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 206010008323 cervicitis Diseases 0.000 description 1
• AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 230000031902 chemoattractant activity Effects 0.000 description 1
• 230000035605 chemotaxis Effects 0.000 description 1
• 235000013330 chicken meat Nutrition 0.000 description 1
• 239000012069 chiral reagent Substances 0.000 description 1
• 229950008249 chlornaphazine Drugs 0.000 description 1
• 229960003677 chloroquine Drugs 0.000 description 1
• 229960002559 chlorotrianisene Drugs 0.000 description 1
• BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 description 1
• 229960001480 chlorozotocin Drugs 0.000 description 1
• 208000003167 cholangitis Diseases 0.000 description 1
• 201000001352 cholecystitis Diseases 0.000 description 1
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
• 239000000544 cholinesterase inhibitor Substances 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 208000007451 chronic bronchitis Diseases 0.000 description 1
• 231100000762 chronic effect Toxicity 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
• 229960001265 ciclosporin Drugs 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 230000004087 circulation Effects 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 230000035602 clotting Effects 0.000 description 1
• 229940047766 co-trimoxazole Drugs 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 229960001338 colchicine Drugs 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 239000000039 congener Substances 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 239000012059 conventional drug carrier Substances 0.000 description 1
• 150000004696 coordination complex Chemical class 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 229910052802 copper Inorganic materials 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
• 229960000258 corticotropin Drugs 0.000 description 1
• 229940072645 coumadin Drugs 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• MLUCVPSAIODCQM-NSCUHMNNSA-N crotonaldehyde Chemical compound C\C=C\C=O MLUCVPSAIODCQM-NSCUHMNNSA-N 0.000 description 1
• MLUCVPSAIODCQM-UHFFFAOYSA-N crotonaldehyde Natural products CC=CC=O MLUCVPSAIODCQM-UHFFFAOYSA-N 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 229960003067 cystine Drugs 0.000 description 1
• 201000003146 cystitis Diseases 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 230000001085 cytostatic effect Effects 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 201000004400 dacryoadenitis Diseases 0.000 description 1
• 229960000640 dactinomycin Drugs 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• 230000007123 defense Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 229960005052 demecolcine Drugs 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 230000003831 deregulation Effects 0.000 description 1
• 229950003913 detorubicin Drugs 0.000 description 1
• 229910052805 deuterium Inorganic materials 0.000 description 1
• 201000010064 diabetes insipidus Diseases 0.000 description 1
• WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
• 229950002389 diaziquone Drugs 0.000 description 1
• RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
• 125000003963 dichloro group Chemical group Cl* 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
• 229960000452 diethylstilbestrol Drugs 0.000 description 1
• 229940043279 diisopropylamine Drugs 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 239000002612 dispersion medium Substances 0.000 description 1
• 125000005883 dithianyl group Chemical group 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
• 229950005454 doxifluridine Drugs 0.000 description 1
• NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
• 229950004683 drostanolone propionate Drugs 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 229940126534 drug product Drugs 0.000 description 1
• 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
• 208000019258 ear infection Diseases 0.000 description 1
• 235000013399 edible fruits Nutrition 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 229950000549 elliptinium acetate Drugs 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 229940073621 enbrel Drugs 0.000 description 1
• 206010014599 encephalitis Diseases 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 206010014665 endocarditis Diseases 0.000 description 1
• 208000001991 endodermal sinus tumor Diseases 0.000 description 1
• 239000006274 endogenous ligand Substances 0.000 description 1
• 201000003914 endometrial carcinoma Diseases 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 229950011487 enocitabine Drugs 0.000 description 1
• 208000010227 enterocolitis Diseases 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 201000010063 epididymitis Diseases 0.000 description 1
• 229960001904 epirubicin Drugs 0.000 description 1
• 208000037828 epithelial carcinoma Diseases 0.000 description 1
• 229950002973 epitiostanol Drugs 0.000 description 1
• 229960001123 epoprostenol Drugs 0.000 description 1
• KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
• 229930013356 epothilone Natural products 0.000 description 1
• QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 description 1
• 229960001433 erlotinib Drugs 0.000 description 1
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
• 229950002017 esorubicin Drugs 0.000 description 1
• 229960001842 estramustine Drugs 0.000 description 1
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
• 229940011871 estrogen Drugs 0.000 description 1
• 239000000262 estrogen Substances 0.000 description 1
• 239000000328 estrogen antagonist Substances 0.000 description 1
• QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
• HHEIMYAXCOIQCJ-UHFFFAOYSA-N ethyl 2,2-dimethylpropanoate Chemical compound CCOC(=O)C(C)(C)C HHEIMYAXCOIQCJ-UHFFFAOYSA-N 0.000 description 1
• PTXRQIPIELXJFH-UHFFFAOYSA-N ethyl 2-benzamidoacetate Chemical compound CCOC(=O)CNC(=O)C1=CC=CC=C1 PTXRQIPIELXJFH-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 229960005237 etoglucid Drugs 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 230000005713 exacerbation Effects 0.000 description 1
• 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
• 238000011347 external beam therapy Methods 0.000 description 1
• 201000006569 extramedullary plasmacytoma Diseases 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 210000001508 eye Anatomy 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 208000024519 eye neoplasm Diseases 0.000 description 1
• 229940043168 fareston Drugs 0.000 description 1
• 239000011790 ferrous sulphate Substances 0.000 description 1
• 235000003891 ferrous sulphate Nutrition 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 229940098448 fibroblast growth factor 7 Drugs 0.000 description 1
• 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 125000004428 fluoroalkoxy group Chemical group 0.000 description 1
• 125000003709 fluoroalkyl group Chemical group 0.000 description 1
• YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
• 229960001751 fluoxymesterone Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• 235000019152 folic acid Nutrition 0.000 description 1
• 239000011724 folic acid Substances 0.000 description 1
• 229960000304 folic acid Drugs 0.000 description 1
• 150000002224 folic acids Chemical class 0.000 description 1
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
• 235000008191 folinic acid Nutrition 0.000 description 1
• 239000011672 folinic acid Substances 0.000 description 1
• 235000020932 food allergy Nutrition 0.000 description 1
• 229960004783 fotemustine Drugs 0.000 description 1
• YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 210000000232 gallbladder Anatomy 0.000 description 1
• 229940044658 gallium nitrate Drugs 0.000 description 1
• 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
• 201000000052 gastrinoma Diseases 0.000 description 1
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229960000578 gemtuzumab Drugs 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 230000004077 genetic alteration Effects 0.000 description 1
• 231100000118 genetic alteration Toxicity 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 210000004392 genitalia Anatomy 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 201000006592 giardiasis Diseases 0.000 description 1
• 208000007565 gingivitis Diseases 0.000 description 1
• 229940080856 gleevec Drugs 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 229940097043 glucuronic acid Drugs 0.000 description 1
• 229960003180 glutathione Drugs 0.000 description 1
• 150000002315 glycerophosphates Chemical class 0.000 description 1
• 229930182470 glycoside Natural products 0.000 description 1
• 230000002710 gonadal effect Effects 0.000 description 1
• 229960002913 goserelin Drugs 0.000 description 1
• 208000030316 grade III meningioma Diseases 0.000 description 1
• 210000000224 granular leucocyte Anatomy 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 239000003966 growth inhibitor Substances 0.000 description 1
• 150000002357 guanidines Chemical class 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 125000000262 haloalkenyl group Chemical group 0.000 description 1
• 125000000232 haloalkynyl group Chemical group 0.000 description 1
• 230000002140 halogenating effect Effects 0.000 description 1
• 208000014829 head and neck neoplasm Diseases 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 208000025750 heavy chain disease Diseases 0.000 description 1
• 201000002222 hemangioblastoma Diseases 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 208000006750 hematuria Diseases 0.000 description 1
• 208000006359 hepatoblastoma Diseases 0.000 description 1
• 229960001340 histamine Drugs 0.000 description 1
• 239000003453 histamine agonist Substances 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 229940125697 hormonal agent Drugs 0.000 description 1
• 239000003667 hormone antagonist Substances 0.000 description 1
• 229940048921 humira Drugs 0.000 description 1
• BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 description 1
• 125000005638 hydrazono group Chemical group 0.000 description 1
• BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• 229960004171 hydroxychloroquine Drugs 0.000 description 1
• 229960002899 hydroxyprogesterone Drugs 0.000 description 1
• 230000001969 hypertrophic effect Effects 0.000 description 1
• 201000006866 hypopharynx cancer Diseases 0.000 description 1
• 230000036543 hypotension Effects 0.000 description 1
• 229940015872 ibandronate Drugs 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 229960000908 idarubicin Drugs 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
• 150000002463 imidates Chemical class 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000007813 immunodeficiency Effects 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 229960001438 immunostimulant agent Drugs 0.000 description 1
• 239000003022 immunostimulating agent Substances 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 239000007943 implant Substances 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 1
• 229950008097 improsulfan Drugs 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 229940073062 imuran Drugs 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 229940060367 inert ingredients Drugs 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 230000004941 influx Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000000266 injurious effect Effects 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 239000002919 insect venom Substances 0.000 description 1
• 206010022437 insomnia Diseases 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
• 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
• 206010022498 insulinoma Diseases 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 239000000138 intercalating agent Substances 0.000 description 1
• 239000012444 intercalating antibiotic Substances 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 201000002696 invasive tubular breast carcinoma Diseases 0.000 description 1
• 229940044173 iodine-125 Drugs 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• 229960001888 ipratropium Drugs 0.000 description 1
• OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
• 201000004614 iritis Diseases 0.000 description 1
• 208000002551 irritable bowel syndrome Diseases 0.000 description 1
• 208000037906 ischaemic injury Diseases 0.000 description 1
• 201000002529 islet cell tumor Diseases 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
• 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• 238000006317 isomerization reaction Methods 0.000 description 1
• 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000005956 isoquinolyl group Chemical group 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 239000007951 isotonicity adjuster Substances 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
• 229960002014 ixabepilone Drugs 0.000 description 1
• 208000018934 joint symptom Diseases 0.000 description 1
• UHEBDUAFKQHUBV-UHFFFAOYSA-N jspy-st000261 Chemical compound C1=CC=C2C3=C(C(=O)NC4)C4=C(C=4C(=CC=C(C=4)COC(C)C)N4CCCOC(=O)CN(C)C)C4=C3CC2=C1 UHEBDUAFKQHUBV-UHFFFAOYSA-N 0.000 description 1
• 208000011379 keloid formation Diseases 0.000 description 1
• 206010023332 keratitis Diseases 0.000 description 1
• 201000010666 keratoconjunctivitis Diseases 0.000 description 1
• 210000000244 kidney pelvis Anatomy 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 210000001821 langerhans cell Anatomy 0.000 description 1
• 208000003849 large cell carcinoma Diseases 0.000 description 1
• 206010023841 laryngeal neoplasm Diseases 0.000 description 1
• 210000000867 larynx Anatomy 0.000 description 1
• 206010024217 lentigo Diseases 0.000 description 1
• 229940115286 lentinan Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 231100000518 lethal Toxicity 0.000 description 1
• 230000001665 lethal effect Effects 0.000 description 1
• 229960003136 leucine Drugs 0.000 description 1
• 229960001691 leucovorin Drugs 0.000 description 1
• 206010024378 leukocytosis Diseases 0.000 description 1
• 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
• 150000002617 leukotrienes Chemical class 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 229960003538 lonidamine Drugs 0.000 description 1
• WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
• 208000012804 lymphangiosarcoma Diseases 0.000 description 1
• 210000004324 lymphatic system Anatomy 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 150000002688 maleic acid derivatives Chemical class 0.000 description 1
• 125000005439 maleimidyl group Chemical class C1(C=CC(N1*)=O)=O 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• 201000004593 malignant giant cell tumor Diseases 0.000 description 1
• 208000006178 malignant mesothelioma Diseases 0.000 description 1
• 208000026037 malignant tumor of neck Diseases 0.000 description 1
• 210000005075 mammary gland Anatomy 0.000 description 1
• 229910052748 manganese Inorganic materials 0.000 description 1
• 239000011572 manganese Substances 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
• 229950008612 mannomustine Drugs 0.000 description 1
• 208000004396 mastitis Diseases 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
• 229960002985 medroxyprogesterone acetate Drugs 0.000 description 1
• 208000030163 medullary breast carcinoma Diseases 0.000 description 1
• 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
• 229960004296 megestrol acetate Drugs 0.000 description 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229950009246 mepitiostane Drugs 0.000 description 1
• HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
• 230000004066 metabolic change Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
• 229960003105 metformin Drugs 0.000 description 1
• FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• KSSLZZVHAGGQFQ-UHFFFAOYSA-N methyl 2,6-difluoro-4-[3-(quinolin-6-ylmethyl)triazolo[4,5-b]pyridin-5-yl]benzoate Chemical compound C1=C(F)C(C(=O)OC)=C(F)C=C1C1=CC=C(N=NN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 KSSLZZVHAGGQFQ-UHFFFAOYSA-N 0.000 description 1
• MKHLTJXMPGNSKU-UHFFFAOYSA-N methyl 2-chloro-4-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]benzoate Chemical compound C1=C(Cl)C(C(=O)OC)=CC=C1C1=CC=C(N=NN2CC=3C(=CC4=NC=CC=C4C=3)F)C2=N1 MKHLTJXMPGNSKU-UHFFFAOYSA-N 0.000 description 1
• KGSIXOOGGCSYTB-UHFFFAOYSA-N methyl 2-methylquinoline-6-carboxylate Chemical compound N1=C(C)C=CC2=CC(C(=O)OC)=CC=C21 KGSIXOOGGCSYTB-UHFFFAOYSA-N 0.000 description 1
• CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• 229960001566 methyltestosterone Drugs 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 239000003094 microcapsule Substances 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 229960005485 mitobronitol Drugs 0.000 description 1
• 229960003539 mitoguazone Drugs 0.000 description 1
• MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
• VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
• 229950010913 mitolactol Drugs 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 229960000350 mitotane Drugs 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 229960005127 montelukast Drugs 0.000 description 1
• 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
• 229940124303 multikinase inhibitor Drugs 0.000 description 1
• 208000037890 multiple organ injury Diseases 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 230000003387 muscular Effects 0.000 description 1
• 210000002346 musculoskeletal system Anatomy 0.000 description 1
• 231100000219 mutagenic Toxicity 0.000 description 1
• 230000003505 mutagenic effect Effects 0.000 description 1
• 208000022155 mycobacterium avium complex disease Diseases 0.000 description 1
• 229960000951 mycophenolic acid Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• 210000001167 myeloblast Anatomy 0.000 description 1
• 208000031225 myocardial ischemia Diseases 0.000 description 1
• 210000004165 myocardium Anatomy 0.000 description 1
• 208000001611 myxosarcoma Diseases 0.000 description 1
• BXGTVNLGPMZLAZ-UHFFFAOYSA-N n'-ethylmethanediimine;hydrochloride Chemical compound Cl.CCN=C=N BXGTVNLGPMZLAZ-UHFFFAOYSA-N 0.000 description 1
• LVMUYSYSVNFDAF-UHFFFAOYSA-N n-(1,3-benzothiazol-6-ylmethyl)-6-chloro-3-nitropyridin-2-amine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1NCC1=CC=C(N=CS2)C2=C1 LVMUYSYSVNFDAF-UHFFFAOYSA-N 0.000 description 1
• WNYIBZHOMJZDKN-UHFFFAOYSA-N n-(2-acetamidoethyl)acetamide Chemical compound CC(=O)NCCNC(C)=O WNYIBZHOMJZDKN-UHFFFAOYSA-N 0.000 description 1
• JCLQBOGMZQPCMD-UHFFFAOYSA-N n-(trifluoromethyl)benzamide;hydrochloride Chemical compound Cl.FC(F)(F)NC(=O)C1=CC=CC=C1 JCLQBOGMZQPCMD-UHFFFAOYSA-N 0.000 description 1
• MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
• NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
• AZQNCKALWIKHIZ-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-2,6-difluoro-4-[3-(quinolin-6-ylmethyl)imidazo[4,5-b]pyridin-5-yl]benzamide Chemical compound C1=C(F)C(C(=O)NCCN(C)C)=C(F)C=C1C1=CC=C(N=CN2CC=3C=C4C=CC=NC4=CC=3)C2=N1 AZQNCKALWIKHIZ-UHFFFAOYSA-N 0.000 description 1
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
• 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 229960004270 nabumetone Drugs 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 201000003631 narcolepsy Diseases 0.000 description 1
• 230000008693 nausea Effects 0.000 description 1
• 229940086322 navelbine Drugs 0.000 description 1
• 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
• QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 229940053128 nerve growth factor Drugs 0.000 description 1
• 201000004931 neurofibromatosis Diseases 0.000 description 1
• 210000000715 neuromuscular junction Anatomy 0.000 description 1
• 229940032018 neurotrophin 3 Drugs 0.000 description 1
• 208000004235 neutropenia Diseases 0.000 description 1
• XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
• 229960002653 nilutamide Drugs 0.000 description 1
• 229960001420 nimustine Drugs 0.000 description 1
• VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
• YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
• 229950008607 nitracrine Drugs 0.000 description 1
• 239000012299 nitrogen atmosphere Substances 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 201000000032 nodular malignant melanoma Diseases 0.000 description 1
• KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
• 229950009266 nogalamycin Drugs 0.000 description 1
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 230000000414 obstructive effect Effects 0.000 description 1
• 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
• 201000008106 ocular cancer Diseases 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical class O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
• 206010030306 omphalitis Diseases 0.000 description 1
• 229950011093 onapristone Drugs 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000006548 oncogenic transformation Effects 0.000 description 1
• 230000000771 oncological effect Effects 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 208000005963 oophoritis Diseases 0.000 description 1
• 239000003538 oral antidiabetic agent Substances 0.000 description 1
• 201000005443 oral cavity cancer Diseases 0.000 description 1
• 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
• 239000008184 oral solid dosage form Substances 0.000 description 1
• 201000005737 orchitis Diseases 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 201000009234 osteosclerotic myeloma Diseases 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 125000005968 oxazolinyl group Chemical group 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 238000004806 packaging method and process Methods 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• 208000021255 pancreatic insulinoma Diseases 0.000 description 1
• 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
• 229960001972 panitumumab Drugs 0.000 description 1
• 239000000123 paper Substances 0.000 description 1
• 201000010198 papillary carcinoma Diseases 0.000 description 1
• 208000003154 papilloma Diseases 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 230000003071 parasitic effect Effects 0.000 description 1
• 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
• 229960001319 parathyroid hormone Drugs 0.000 description 1
• 239000000199 parathyroid hormone Substances 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
• 150000002960 penicillins Chemical class 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
• 229950003180 peplomycin Drugs 0.000 description 1
• VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
• 208000008494 pericarditis Diseases 0.000 description 1
• 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
• 206010034674 peritonitis Diseases 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 201000008006 pharynx cancer Diseases 0.000 description 1
• 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
• 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
• 208000001297 phlebitis Diseases 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
• 238000002428 photodynamic therapy Methods 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 201000003113 pineoblastoma Diseases 0.000 description 1
• 206010035059 pineocytoma Diseases 0.000 description 1
• NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
• 229960000952 pipobroman Drugs 0.000 description 1
• NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
• 229950001100 piposulfan Drugs 0.000 description 1
• 229960001221 pirarubicin Drugs 0.000 description 1
• 201000002511 pituitary cancer Diseases 0.000 description 1
• 229950010765 pivalate Drugs 0.000 description 1
• IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
• 229940072689 plaquenil Drugs 0.000 description 1
• 208000031223 plasma cell leukemia Diseases 0.000 description 1
• 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
• 108010000685 platelet-derived growth factor AB Proteins 0.000 description 1
• 229910052697 platinum Inorganic materials 0.000 description 1
• 150000003057 platinum Chemical class 0.000 description 1
• 210000003281 pleural cavity Anatomy 0.000 description 1
• 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
• 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 1
• 208000037244 polycythemia vera Diseases 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 208000015768 polyposis Diseases 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 229920002451 polyvinyl alcohol Polymers 0.000 description 1
• 239000000276 potassium ferrocyanide Substances 0.000 description 1
• TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
• RFAKLMBNSZNUNX-UHFFFAOYSA-N potassium;isothiocyanate Chemical compound [K+].[N-]=C=S RFAKLMBNSZNUNX-UHFFFAOYSA-N 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 244000144977 poultry Species 0.000 description 1
• 235000013594 poultry meat Nutrition 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 229960004694 prednimustine Drugs 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 208000030266 primary brain neoplasm Diseases 0.000 description 1
• 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
• 229950003608 prinomastat Drugs 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 239000000583 progesterone congener Substances 0.000 description 1
• 239000002325 prokinetic agent Substances 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 210000004765 promyelocyte Anatomy 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 229940127293 prostanoid Drugs 0.000 description 1
• 150000003814 prostanoids Chemical class 0.000 description 1
• 201000007094 prostatitis Diseases 0.000 description 1
• 239000003909 protein kinase inhibitor Substances 0.000 description 1
• 239000000007 protein synthesis inhibitor Substances 0.000 description 1
• 201000001474 proteinuria Diseases 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
• 201000003651 pulmonary sarcoidosis Diseases 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 229950010131 puromycin Drugs 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 description 1
• RZIPENSSTUBRAA-UHFFFAOYSA-N quinolin-6-ylmethanamine Chemical compound N1=CC=CC2=CC(CN)=CC=C21 RZIPENSSTUBRAA-UHFFFAOYSA-N 0.000 description 1
• NIFLNJLWZZABMI-UHFFFAOYSA-N quinoline-6-carbonitrile Chemical compound N1=CC=CC2=CC(C#N)=CC=C21 NIFLNJLWZZABMI-UHFFFAOYSA-N 0.000 description 1
• YMNAJWHTELQUJU-UHFFFAOYSA-N quinoline-6-carboxamide Chemical compound N1=CC=CC2=CC(C(=O)N)=CC=C21 YMNAJWHTELQUJU-UHFFFAOYSA-N 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 239000002331 radioactive microsphere Substances 0.000 description 1
• 238000007674 radiofrequency ablation Methods 0.000 description 1
• 229960002185 ranimustine Drugs 0.000 description 1
• BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
• 229960000460 razoxane Drugs 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 229940038850 rebif Drugs 0.000 description 1
• 102000019107 receptor ligand activity proteins Human genes 0.000 description 1
• 108040008338 receptor ligand activity proteins Proteins 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 238000005932 reductive alkylation reaction Methods 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 239000003488 releasing hormone Substances 0.000 description 1
• 229940116176 remicade Drugs 0.000 description 1
• 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
• 201000002793 renal fibrosis Diseases 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 230000029058 respiratory gaseous exchange Effects 0.000 description 1
• 210000002345 respiratory system Anatomy 0.000 description 1
• 208000023504 respiratory system disease Diseases 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 229930002330 retinoic acid Natural products 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 108091092562 ribozyme Proteins 0.000 description 1
• 229950004892 rodorubicin Drugs 0.000 description 1
• RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
• 229960000371 rofecoxib Drugs 0.000 description 1
• VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000036573 scar formation Effects 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 208000013223 septicemia Diseases 0.000 description 1
• 206010040400 serum sickness Diseases 0.000 description 1
• 206010040560 shock Diseases 0.000 description 1
• 229950001403 sizofiran Drugs 0.000 description 1
• 201000002859 sleep apnea Diseases 0.000 description 1
• 208000019116 sleep disease Diseases 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 208000000649 small cell carcinoma Diseases 0.000 description 1
• 208000010721 smoldering plasma cell myeloma Diseases 0.000 description 1
• QEZKMMVSLTZOJP-UHFFFAOYSA-M sodium [2,6-difluoro-4-[3-[(7-fluoroquinolin-6-yl)methyl]triazolo[4,5-b]pyridin-5-yl]benzoyl]-(2-hydroxyethoxy)azanide Chemical compound [Na+].OCCO[N-]C(=O)c1c(F)cc(cc1F)-c1ccc2nnn(Cc3cc4cccnc4cc3F)c2n1 QEZKMMVSLTZOJP-UHFFFAOYSA-M 0.000 description 1
• 239000003195 sodium channel blocking agent Substances 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 229960003787 sorafenib Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 230000035886 specific defense system Effects 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 229940046810 spiriva Drugs 0.000 description 1
• 229950006315 spirogermanium Drugs 0.000 description 1
• 230000003393 splenic effect Effects 0.000 description 1
• 229940068117 sprycel Drugs 0.000 description 1
• 102000009076 src-Family Kinases Human genes 0.000 description 1
• 108010087686 src-Family Kinases Proteins 0.000 description 1
• 238000011476 stem cell transplantation Methods 0.000 description 1
• 238000002719 stereotactic radiosurgery Methods 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 208000003265 stomatitis Diseases 0.000 description 1
• 229960005202 streptokinase Drugs 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 1
• 229940006509 strontium-89 Drugs 0.000 description 1
• 201000008262 subacute glomerulonephritis Diseases 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 125000005415 substituted alkoxy group Chemical group 0.000 description 1
• 125000000547 substituted alkyl group Chemical group 0.000 description 1
• 150000003890 succinate salts Chemical class 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
• 229940124530 sulfonamide Drugs 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 150000003457 sulfones Chemical class 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 229910021653 sulphate ion Inorganic materials 0.000 description 1
• 229960001796 sunitinib Drugs 0.000 description 1
• 208000030457 superficial spreading melanoma Diseases 0.000 description 1
• 201000010965 sweat gland carcinoma Diseases 0.000 description 1
• 229940127230 sympathomimetic drug Drugs 0.000 description 1
• 201000004595 synovitis Diseases 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
• 229940063683 taxotere Drugs 0.000 description 1
• 229960001674 tegafur Drugs 0.000 description 1
• WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
• 201000004415 tendinitis Diseases 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 229960005353 testolactone Drugs 0.000 description 1
• BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
• XOGGUFAVLNCTRS-UHFFFAOYSA-N tetrapotassium;iron(2+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] XOGGUFAVLNCTRS-UHFFFAOYSA-N 0.000 description 1
• 125000001113 thiadiazolyl group Chemical group 0.000 description 1
• 235000019157 thiamine Nutrition 0.000 description 1
• KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
• 229960003495 thiamine Drugs 0.000 description 1
• 239000011721 thiamine Substances 0.000 description 1
• 125000002769 thiazolinyl group Chemical group 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 229960000103 thrombolytic agent Drugs 0.000 description 1
• 201000009377 thymus cancer Diseases 0.000 description 1
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
• 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
• YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
• 229950011457 tiamiprine Drugs 0.000 description 1
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 229960001017 tolmetin Drugs 0.000 description 1
• UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
• 206010044008 tonsillitis Diseases 0.000 description 1
• 229960005026 toremifene Drugs 0.000 description 1
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
• 229960005267 tositumomab Drugs 0.000 description 1
• 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
• 229940072041 transforming growth factor beta 2 Drugs 0.000 description 1
• 108010033898 transforming growth factor beta1.2 Proteins 0.000 description 1
• 208000037918 transfusion-transmitted disease Diseases 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• 230000009529 traumatic brain injury Effects 0.000 description 1
• IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
• 229950001353 tretamine Drugs 0.000 description 1
• 229960001727 tretinoin Drugs 0.000 description 1
• GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
• 229960005294 triamcinolone Drugs 0.000 description 1
• PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
• 229960004560 triaziquone Drugs 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
• 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
• WRTSXKKAXLYBSH-UHFFFAOYSA-N trifluoromethyl benzoate Chemical compound FC(F)(F)OC(=O)C1=CC=CC=C1 WRTSXKKAXLYBSH-UHFFFAOYSA-N 0.000 description 1
• 229960001670 trilostane Drugs 0.000 description 1
• KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
• NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
• 229960001099 trimetrexate Drugs 0.000 description 1
• 229950000212 trioxifene Drugs 0.000 description 1
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
• 125000005455 trithianyl group Chemical group 0.000 description 1
• 229960000875 trofosfamide Drugs 0.000 description 1
• UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
• 201000002311 trypanosomiasis Diseases 0.000 description 1
• HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 210000004881 tumor cell Anatomy 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 229950009811 ubenimex Drugs 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 238000011144 upstream manufacturing Methods 0.000 description 1
• 229960001055 uracil mustard Drugs 0.000 description 1
• 208000019206 urinary tract infection Diseases 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 229960005356 urokinase Drugs 0.000 description 1
• 208000023747 urothelial carcinoma Diseases 0.000 description 1
• 208000037965 uterine sarcoma Diseases 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 206010046885 vaginal cancer Diseases 0.000 description 1
• 208000013139 vaginal neoplasm Diseases 0.000 description 1
• LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
• 229960002004 valdecoxib Drugs 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 229960004295 valine Drugs 0.000 description 1
• 229960000241 vandetanib Drugs 0.000 description 1
• UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
• 208000021331 vascular occlusion disease Diseases 0.000 description 1
• 238000007631 vascular surgery Methods 0.000 description 1
• 239000004066 vascular targeting agent Substances 0.000 description 1
• 230000002227 vasoactive effect Effects 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 229960003726 vasopressin Drugs 0.000 description 1
• 229950000578 vatalanib Drugs 0.000 description 1
• YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
• 231100000611 venom Toxicity 0.000 description 1
• 208000034280 venom allergy Diseases 0.000 description 1
• 208000008662 verrucous carcinoma Diseases 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
• 235000019155 vitamin A Nutrition 0.000 description 1
• 239000011719 vitamin A Substances 0.000 description 1
• 235000019156 vitamin B Nutrition 0.000 description 1
• 239000011720 vitamin B Substances 0.000 description 1
• 235000019166 vitamin D Nutrition 0.000 description 1
• 239000011710 vitamin D Substances 0.000 description 1
• 150000003710 vitamin D derivatives Chemical class 0.000 description 1
• MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
• 235000019165 vitamin E Nutrition 0.000 description 1
• 239000011709 vitamin E Substances 0.000 description 1
• 239000011712 vitamin K Substances 0.000 description 1
• 235000019168 vitamin K Nutrition 0.000 description 1
• 229940046001 vitamin b complex Drugs 0.000 description 1
• 229940046008 vitamin d Drugs 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 201000005102 vulva cancer Diseases 0.000 description 1
• 208000002003 vulvitis Diseases 0.000 description 1
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 210000002268 wool Anatomy 0.000 description 1
• 229940053867 xeloda Drugs 0.000 description 1
• 229940099073 xolair Drugs 0.000 description 1
• 239000000811 xylitol Substances 0.000 description 1
• HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
• 235000010447 xylitol Nutrition 0.000 description 1
• 229960002675 xylitol Drugs 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
• 229950009268 zinostatin Drugs 0.000 description 1
• 229940033942 zoladex Drugs 0.000 description 1
• FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
• 229960000641 zorubicin Drugs 0.000 description 1